





Review

# Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis

Yun Chen<sup>1 2 5 6 7 8</sup>, Michael R. Strickland<sup>1 2 5 6 8</sup>, Andrea Soranno<sup>3 4</sup>, David M. Holtzman<sup>1 4 5</sup>  

Show more 

 Outline |  Share  Cite

<https://doi.org/10.1016/j.neuron.2020.10.008> 


[Get rights and content](#) 

Under an Elsevier [user license](#) 

[open archive](#)

## Summary

Apolipoprotein E (ApoE) is of great interest due to its role as a cholesterol/lipid transporter in the central nervous system (CNS) and as the most influential genetic risk factor for Alzheimer disease (AD). Work over the last four decades has given us important insights into the structure of ApoE and how this might impact the neuropathology and pathogenesis of AD. In this review, we highlight the history and progress in the structural and molecular understanding of ApoE and discuss how these studies on ApoE have illuminated the physiology of ApoE, receptor binding, and interaction with amyloid- $\beta$  ( $A\beta$ ). We also identify future areas of study needed to advance our understanding of how ApoE influences neurodegeneration.




## Keywords

Apolipoprotein E; ApoE; Amyloid- $\beta$ ; A $\beta$ ; Alzheimer disease; AD; low-density lipoprotein receptor; LDLR

---

## Introduction

Apolipoprotein E (ApoE) was first identified in the 1970s as one of the protein components of plasma very-low-density lipoprotein (VLDL) ([Shore and Shore, 1973](#); [Utermann, 1975](#)). It was found to play a critical role in plasma cholesterol metabolism and was soon realized to be a major risk factor in atherosclerosis and hypercholesterolemia ([Mahley, 1988](#); [Mahley et al., 2009](#)). Early characterization of ApoE revealed six protein polymorphisms, separable by two-dimensional gel electrophoresis ([Davignon et al., 1988](#); [Rall et al., 1983](#)). In humans, three of these polymorphisms are due to the presence of three ApoE isoforms (ApoE2, ApoE3, and ApoE4) characterized by a single amino acid substitution in ApoE2 and ApoE4, compared to the most prevalent isoform, ApoE3. The 3 other polymorphisms present in ApoE result from variable sialylation at Thr194 ([Wernette-Hammond et al., 1989](#)). Despite the impact on disease risk, ApoE isoforms differ from each other in its 299 amino acids at only two sites: ApoE4 is characterized by Arg112 and Arg158, ApoE3 by Cys112 and Arg158, and ApoE2 by Cys112 and Cys158 ([Figure 1A](#)) ([Weisgraber, 1994](#)). Soon after the initial discovery of ApoE, the primary receptor for ApoE—low-density lipoprotein receptor (LDLR)—was discovered in 1976 ([Goldstein and Brown, 1976](#)). Subsequent studies showed that ApoE was one of the primary ligands for LDLR, in addition to Apolipoprotein B ([Innerarity and Mahley, 1978](#)). Through its interaction with LDLR, ApoE plays a critical role in cellular uptake of ApoE-containing lipoproteins ([Weisgraber, 1994](#)).



[Download: Download high-res image \(642KB\)](#)

[Download: Download full-size image](#)

Figure 1. Illustration of Domains and Single-Residue Substitutions of ApoE Isoforms

(A) Figure shows early domain categorizations of ApoE with thrombin cleavage. Red: the N-terminal domain of ApoE (1–167); yellow: the LDLR receptor binding domain (136–150); gray: the hinge region (167–206) where cleavage site is located; blue: the C-terminal domain (206–299). Also, the amino acids that distinguish the different ApoE isoforms are shown at position 112 and 158. ApoE2 is characterized by cysteine at positions 112 and 158, ApoE3 by cysteine at position 112 and arginine at position 158, and ApoE4 by arginine at positions 112 and 158.

(B) The full-length 3D structure of ApoE3 by NMR (PDB:2I7b ↗). This demonstrates the folding and interaction between the N-terminal, hinge, and C-terminal protein domains. Colors are coded to illustrate the different domains of ApoE mentioned in [Figure 1A](#).

(C) Positions of single-residue substitution among ApoE isoforms shown in 3D structure. ApoE2: Cys112 and Cys 158; ApoE3: Cys112 and Arg158; ApoE4: Arg112 and Arg 158. Figures are generated from PDB files from left to right: 1le2, 1ple, 1le4.

In addition to the critical role that ApoE plays in peripheral cholesterol metabolism, ApoE was found to be the primary apolipoprotein lipid and cholesterol transporter in the central nervous system (CNS) (Boyles et al., 1985; Mahley, 1988). ApoE is produced by almost all cell types in the brain: astrocytes, which secrete the vast majority of ApoE under physiological conditions; microglia, under pathological conditions; and neurons, under certain injury conditions (Blue et al., 1983; Boyles et al., 1985; DeMattos et al., 1998; Newman et al., 1985; Pitas et al., 1987; Weisgraber, 1994; Williams et al., 1985). Characterization of ApoE secreted from astrocytes revealed that ApoE is secreted in lipoprotein particles similar in size to high-density lipoproteins (HDLs) (Fagan et al., 1999; Pitas et al., 1987). In 1993, *APOE* genotype was found to strongly modulate risk for Alzheimer disease (AD) (Corder et al., 1993; Strittmatter et al., 1993a, 1993b). A single copy of the  $\epsilon 4$  allele increases AD risk by about 3-fold, with two copies of the  $\epsilon 4$  allele increasing disease risk about 12-fold relative to individuals who have 2 copies of the  $\epsilon 3$  allele. The  $\epsilon 2$  allele decreases AD risk by about 0.6 (Corder et al., 1993; Holtzman et al., 2012). ApoE was also identified as a core component in cerebral and vascular amyloid plaques (Näslund et al., 1995; Wisniewski and Frangione, 1992). Early studies with amyloid- $\beta$  (A $\beta$ ) depositing mice (PDAPP or Tg2576 mice) mice found that, in the absence of murine ApoE, A $\beta$  still deposited in the brain but did not form or formed very little  $\beta$ -pleated sheet structures in the brain parenchyma or in cerebral amyloid angiopathy (CAA) (Bales et al., 1997; Holtzman et al., 2000). Interestingly, expression of human ApoE3 and ApoE4 in PDAPP mice in the absence of murine ApoE delayed the onset of A $\beta$  deposition relative to mouse ApoE or no ApoE, suggesting that human ApoE may play role in A $\beta$  clearance as well as in A $\beta$  fibril formation (Holtzman et al., 1999). Later studies in PDAPP mice expressing human ApoE2, ApoE3, and ApoE4 revealed that the amount of A $\beta$  pathology is dependent on ApoE isoform: ApoE4 leads to the most A $\beta$  pathology and ApoE2 the least with ApoE3 being intermediate between the two other isoforms (Bales et al., 2009; Fagan et al., 2002; Holtzman et al., 2000). Similar ApoE isoform-dependent effects on A $\beta$  were seen in different APP/PS1 transgenic mice (Kim et al., 2011; Kuszczuk et al., 2013; Youmans et al., 2012). Apart from ApoE-A $\beta$  interaction, it was reported that ApoE isoform modulates extracellular, soluble, monomeric A $\beta$  levels (Castellano et al., 2011) and that the levels of ApoE receptors, such as LDLR or LRP1, also modulate A $\beta$  pathology (Kanekiyo et al., 2013; Kim et al., 2009; Verghese et al., 2013). In addition to the importance of ApoE in A $\beta$  pathology, ApoE has been shown to dramatically impact neurodegeneration in a mouse model of tauopathy (Shi et al., 2017). Similar to the effect of ApoE isoform on A $\beta$  pathology, increased neurodegeneration was observed with

ApoE4 compared to ApoE3 and ApoE2, while the absence of ApoE was neuroprotective. Due to its pleiotropic effects, ApoE may influence AD in other ways, including effects on the blood-brain barrier, synaptic plasticity, and possibly other mechanisms (Bell et al., 2012; Liu et al., 2013). In addition to AD, ApoE has also been reported to have an impact on dementia and synucleinopathy in Parkinson's disease dementia and dementia with Lewy bodies as well as in mouse models of synucleinopathy (Davis et al., 2020; Dickson et al., 2018; Tsuang et al., 2013; Zhao et al., 2020).

The dramatic effect of ApoE isoform on AD, neurodegeneration, and other neuropathologies is likely the consequence of both the direct interaction of ApoE with specific proteins such as A $\beta$  and ApoE receptors, as well as indirectly through regulation of ApoE levels by the interaction of ApoE with its receptors and other molecules. Some early studies have suggested that ApoE may directly interact with A $\beta$  to induce A $\beta$  fibrillization (Aleshkov et al., 1997; LaDu et al., 1994; Ma et al., 1994; Strittmatter et al., 1993b; Wisniewski et al., 1993). In fact, our lab also recently discovered that the ApoE in A $\beta$  plaques exists in a unique conformation that is not lipidated that may promote A $\beta$  plaque formation (Liao et al., 2018). On the other hand, ApoE2 may be protective due to deficiencies in ApoE-LDLR binding (Hui et al., 1984; Rall et al., 1983) or via other effects. Modulation of LDL receptors, including LDLR and LRP1, has been demonstrated to affect A $\beta$  clearance by different groups (Cam et al., 2005; Castellano et al., 2012; Kim et al., 2009). To better understand and develop treatment for AD and other neurodegenerative disorders, it will be critical to investigate the molecular interactions that occur between ApoE, pathological proteins, ApoE receptors, and other interacting molecules. Indeed, much progress has been made in the last 40 years to elucidate the molecular behavior of ApoE and its impact on neurodegeneration. Advances in understanding the structure of ApoE have yielded insights into how seemingly small changes at the structural level manifest themselves as dramatic changes in ApoE receptor binding and AD pathology. In this review, we discuss the historical progress in understanding ApoE structure and how these insights can be used to better understand AD neuropathology and pathogenesis. We will also discuss new directions that will be necessary to further advance our understanding of ApoE structure/function relationships.

## Historical Progress in Understanding ApoE Structure


Soon after the discovery of ApoE (Shore and Shore, 1973), structural predictions were proposed based on the primary sequence of ApoE (Baker et al., 1975; Weisgraber 1994). Biochemists and evolutionary biologists have focused on conservative internal repeats of the primary amino acid sequences that exist in most apolipoproteins (

Huebbe and Rimbach, 2017; Li et al., 1988). These internal repeats exhibit features that are favorable for forming amphiphilic  $\alpha$ -helical structures according to the primary amino acid sequence (Li et al., 1988; Weisgraber 1994). Such amphiphilic helices supported the amphiphilic theory that charged residues create electrostatic association with lipid head groups, and their adjacent hydrophobic residues further stabilize the neck of those phospholipids on lipoprotein particles. The predicted helical secondary structures were experimentally verified by circular dichroism (CD) spectra (Weisgraber, 1994). More interestingly, it was also shown that the heparin-binding domain of ApoE extended the helical portion in the presence of heparin or other glycosaminoglycans (Cardin et al., 1991; Mahley et al., 1979), strengthening the belief that the helical structures in the apolipoprotein family are required to interact with lipids on lipoprotein particles (Jackson et al., 1975).

Thrombolytic cleavage of the ApoE molecule yields two unique fragments, the N-terminal domain and C-terminal domain, where the N-terminal domain is responsible for LDLR binding, but only weakly interacts with lipids, and the C-terminal is considered to bind to the surface of lipoproteins and is not involved in LDLR recognition (Figures 1A and 1B) (Bradley et al., 1982; Innerarity et al., 1983; Weisgraber, 1990). However, while point mutagenesis and antibody competition experiments have unveiled that residues 136–150 are required for LDLR binding to ApoE (Innerarity et al., 1983; Lalazar et al., 1988; Weisgraber et al., 1983; Wilson et al., 1991), the single-residue replacement of arginine by cysteine at position 158 on ApoE2 (Figures 1A and 1C), seemingly distant from the LDLR binding site, dramatically reduces the binding of ApoE2 to LDLR. In addition, while DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) associated full-length ApoE2 has a significant reduction in affinity for LDLR (Weisgraber et al., 1982), the N-terminal truncated form of ApoE2 regains partial binding ability when bound to DMPC (Yamamoto et al., 2007). The ApoE4 amino acid change of Cys112 to Arg112 (Figures 1A and 1C), that is also not part of the LDLR binding site (136–150), is strongly associated with increased cholesterol and LDL in plasma (Eto et al., 1987, 1991; Saito et al., 2004). These observations contributed to delineate a critical question that has defined the field: how do these single amino acid substitutions dramatically change the characteristics of ApoE-containing lipoprotein particles and their binding properties to other molecules, consequently impacting on AD pathology?

This question was first addressed by the crystal structure of a recombinant N-terminal portion of human ApoE3 expressed in *E. coli* (Aggerbeck et al., 1988; Wilson et al., 1991). While building one of the first vertebrate apolipoprotein structures (Wilson et al., 1991; Breiter et al., 1991), Wilson et al. achieved a density map at 2.5Å resolution for *de novo* modeling generated from dimethyl mercury labeling and combined heavy atom phase

refinement. According to their structural model, the major N-terminal portion of human ApoE3 exhibits an elongated four-antiparallel-helix bundle. This helix bundle buries most of the hydrophobic residues inside a compact core and exposes the hydrophilic residues on the surface, where the repeating leucine residues stack with each other with leucine side chains from adjacent antiparallel helices and further “zipper” the helical bundle. Moreover, seven salt bridges were observed to form between pairs of helices, further stabilizing the super-secondary structure. On the other hand, supporting previous determinations of the LDLR binding site ([Weisgraber, 1994](#)), the structure described by Wilson et al. revealed that many basic residues, such as Arg134, Arg136, His140, Arg142, Lys143 Arg145, Lys146, Arg147, and Arg150, are mostly accessible on the surface and free from intramolecular salt bridges, forming a strong basic site for LDLR binding ([Figure 2A](#)). It also explains why none of the naturally occurring variants or single-point mutagenesis in that region could completely eliminate the ApoE-LDLR interaction, because all these basic residues may cooperatively interact with LDLR and foster a high binding affinity ([Innerarity et al., 1983](#); [Lalazar et al., 1988](#); [Landschulz et al., 1996](#); [Mann et al., 1989](#)).



[Download: Download high-res image \(1MB\)](#)

[Download: Download full-size image](#)

Figure2. Structural Analysis Focusing on LDLR Binding Regions on ApoE

(A) Putative explanation of isoform differences in affecting LDLR binding region from crystal structures. From left to right: ApoE2, ApoE3, ApoE4, and ApoE2\_D154A. Red ellipses



highlight the key Arg150 only captured by Asp154 in ApoE2 that affects LDLR binding site. Red arrows indicate different orientations of Arg150 in those structures. Gray rectangles show the LDLR binding sites on ApoE structures. PDB files from left to right: 1le2, 1ple, 1le4, 1nfo.


(B) NMR structure of full-length ApoE3 (PDB: [2I7b ↗](#)). Salmon: N-terminal residues (1–24); cyan: N-terminal  $\alpha$ -helix bundle (25–163); yellow: free loop (164–168); gray: hinge region; red: C-terminal. Cyan structure shows the  $\alpha$ -helix bundle consistent with previous X-ray crystal structures. Yellow loop highlights the “lock” of N-terminal  $\alpha$ -helix bundle to unfold. The gray hinge region and red C-terminal domain cover N-terminal  $\alpha$ -helix bundle that was assumed solvent exposed.

(C) NMR structure of full-length ApoE3 showed that LDLR binding region is completely covered in non-lipidated form. Top-left panel shows the superposition of crystal structure of ApoE3 N-terminal domain (green, PDB: [1lpe ↗](#)) to NMR structure (cyan and red, PDB: [2I7b ↗](#)), key residues involved in LDLR binding are highlighted with hydrogen atoms (white); top-middle panel shows that LDLR binding site on N-terminal domain of ApoE3 is completely capped by C-terminal (red dots represent the atomic surface of C-terminal domain); top-right panel highlights key interactions between acidic residues on C-terminal domain and basic residues in LDLR binding, enlarged views of three interaction cores between N-terminal and C-terminal domains are presented at the bottom. Note: Q279 and E287 are mutations generated by the authors.

---

Prompted by this pioneering work, the similar N-terminal fragment of ApoE4 and ApoE2 was resolved by X-ray crystallography ([Dong et al., 1994](#); [Wilson et al., 1994](#)). Combining all these N-terminal crystal structures, an intriguing structural model was proposed by Weisgraber and colleagues to explain the differences in ApoE isoforms ([Figure 3A](#)) ([Weisgraber, 1994](#)). This model consists of a N-terminal four helix bundle and an undetermined  $\alpha$ -helical C-terminal region connected by a hinge domain ([Figure 3A](#)). ApoE possesses many Lys and Arg residues in the Helix 4 in the N-terminal helical bundle, creating a positively charged pocket to interact with acidic residues in the lipoprotein binding site on LDLR protein family members. Meanwhile, lipid association with ApoE would induce a conformational change of the N-terminal and hinge region, especially recruiting Arg172 in the hinge region to fully activate the LDLR binding affinity of ApoE ([Morrow et al., 2000](#)). Such a conformational change induced by lipid binding is thought to initiate in the C-terminal domain, because, unlike the C-terminal domain, the isolated N-terminal domain showed little lipid binding ability ([Bradley et al., 1982](#); [Innerarity et al., 1983](#); [Weisgraber, 1990](#)). On the other hand, compared with ApoE3, the single-residue substitution on ApoE2—R158C—releases the Asp154 to form a new salt bridge

with Arg150 and therefore disrupts the initiation of LDLR-ApoE interaction starting with Arg150 and the adjacent basic residues (Figure 2A). Weisgraber's idea was supported by a point mutagenesis that switched Asp154 to Ala and successfully restored the LDLR binding affinity of mutant ApoE2 (Figure 2A) (Dong and Weisgraber, 1996). On the other hand, the ApoE4 change—C112R—was proposed to be involved in a putative interaction with Glu255 in the C-terminal region (Figure 3A). The first evidence for this came from the N-terminal structure resolved by the Weisgraber and Agard group, in which the substitution C112R pushed Arg 61 away from the helix bundle, while in ApoE3 Arg61 was buried between two helices (Dong et al., 1994). The second evidence was from a mutagenesis study that demonstrated a single mutation E255A changed ApoE4's preference in plasma LDL binding to HDL like ApoE2 and ApoE3 (Saito et al., 2003). To address these observations, Weisgraber and colleagues hypothesized that there is an interaction between Arg61 and Glu255 caused by Arg112 in ApoE4 that locks ApoE4 in a less open conformation compared to ApoE2 and ApoE3, rendering a much tighter interaction between the N-terminal domain and C-terminal domain (Figure 3A) (Hatters et al., 2005; Xu et al., 2004). Mutagenesis of Glu109 in ApoE3 and Arg61 in ApoE4 also supported the idea that the position of Arg61 in ApoE4 is critical in determining ApoE4 plasma VLDL binding preference (Dong et al., 1994; Dong and Weisgraber, 1996). The relevance of such a lipoprotein preference based on this model might be relevant in the plasma where large lipoproteins such as LDL and VLDL exist. Although only HDL-like lipoparticles exist in the CNS, these findings may also be important in understanding size differences in ApoE-lipoprotein particles secreted from different cell types. Of note, the other rearrangements of the salt bridges on helix 3 in ApoE2 may not completely explain its lack of binding to LDLR (Weisgraber, 1994; Wilson et al., 1991), and these N-terminal structures also provided no information of other key residues for ApoE-LDLR interaction such as arginine 172 (Morrow et al., 2000). The lack of the integral view on full-length ApoE molecular structure has hampered the interpretations of increasing pathological observations that linked ApoE to AD pathology for years.



[Download: Download high-res image \(969KB\)](#)

[Download: Download full-size image](#)

Figure 3. Two Structural Models of Lipidated ApoE Lipoprotein Particle

(A) Early ApoE lipidation and explanation of isoform differences in lipidation, adapted from [Mahley et al. \(2009\)](#). Left panel shows the impact of Arg112 substitution in ApoE4 on strengthening N/C-terminal domain interaction (Arg61-Glu255) comparing to ApoE3.

(B) Figure shows the “horse-shoe” structural model fit into low-resolution electronic density map from X-ray diffraction data by Weisgraber’s group. LDLR binding region is circled in red. Adapted from [Mahley et al. \(2009\)](#).

(C) Cartoon adapted from [Peters-Libeu et al. \(2006\)](#), presents a cartoon model how the “horse-shoe” ApoE monomer curves on lipoparticles based on the X-ray crystallography data.

(D) Cartoon adapted from [Peters-Libeu et al. \(2006\)](#), showing a dimeric packing of two ApoE molecules on each repeat unit of ApoE-DPPC.

(E) Molecular dynamic simulation results of ApoE4 dimers on a lipid disc, adapted from [Henry et al. \(2018\)](#). From top to bottom show different possible configurations of two ApoE4 molecules wrapping around a lipid disc.

Adapted from [Mahley et al., 2009](#); [Peters-Libeu et al., 2006](#); [Henry et al., 2018](#)

---

It wasn't until 2011, that the first full-length ApoE structure was resolved by the group of Jiajun Wang by nuclear magnetic resonance (NMR), though this was done with multiple mutations (R215C/R217S/F257A/W264R/V269A/L279Q/V287E) needed to stabilize ApoE3 in a monomeric form ([Zhao et al., 2018](#); [Chen et al., 2011](#)). Their structural model successfully extended the N-terminal models from X-ray crystallography and previous NMR structure of the C-terminal domain, in which the N-terminal domain (residues 1–167) and C-terminal domain (residues 206–299) are shown to link together by a long hinge domain (residues 168–205) ([Figure 2B](#)). This NMR structure showed that the folding and unfolding process of ApoE could potentially be much more complicated than suggested by the Weisgraber model ([Figure 2C](#)). According to their full-length NMR structure of human ApoE3, the N-terminal four helix bundle possesses similar configurations compared to previous N-terminal truncated structures, except for some minor changes: the existence of the C-terminal domain attracts the helix 1' (45–52) to slide down and results in helices 3 (89–125) and 4 (131–164) subtly tilted toward the C-terminal domain. The long hinge domain forms two more helices that tightly cover the hydrophobic surface on helix 2 and 3 of the N-terminal domain, regulating the interaction between N- and C-terminal domains. The C-terminal domain ultimately turns to fold into one curved long helix and two short helical structures that cover the other side of N-terminal domain helix bundle ([Figure 2B](#)). Indeed, the general folding of the N-terminal and C-terminal helices are consistent with previous structures ([Figure 2B](#)). However, if the mutated residues do not significantly alter ApoE structure, then this full-length ApoE3 structure would change our understanding of molecular characteristics of ApoE and its interaction with lipids or even receptors, such as LDLR or its family members because of its unique topology. First, the hinge region forms two helices instead of completely random coils that partially cover the surface of the N-terminal helix bundle. Second, the enshrouding superposition by the loop between hinge helix and helix 4 on top of the loop between helix 2 and 3 forces ApoE3 to undergo a unique unfolding process compared to what was previously proposed ([Weisgraber, 1994](#)). Last but not least, the major region of LDLR binding site on in the N-terminal domain is in fact shielded by the C-terminal domain containing helices and intrinsic disordered regions instead of simply G helices ([Figure 2C](#)). The key arginine 150 may not be free from interactions with multiple

residues in the C-terminal domain including Gln253, Glu281, and Glu287. Moreover, the proposed original salt bridges become more complicated as residues Asp154 and Arg158 also interact with Lys157, Arg260, Gln275, and Gln279 ([Figure 2C](#)). Also, the sole substitution in ApoE2—C112R—may alter the unfolding process or affinity since Arg158 is predicted to be involved in dissociation of helix 3 and helix 4 and the final dimerization between two stretched ApoE3 monomers ([Chen et al., 2011](#)). Wang's group also pointed out that the previously predicted domain interaction through Arg61 and Glu255 was not present in their model. Rather, the interaction between the N-terminal and C-terminal domain is proposed to occur between Lys95 and Glu255. However, Gln279 and Glu287 were in fact induced for NMR restraints and turned out to be strongly involved in those interactions ([Figure 2C](#)). Whether the covering of the C-terminal domain onto N-terminal helical bundle comes from an artifact is never clearly discussed. Moreover, since physiological ApoE is lipidated it is unclear whether the shielding of the N-terminal domain by the C-terminal domain is physiologically significant.

This structure eventually leads to the most comprehensive and rigorous model for ApoE folding and lipidation process proposed. Carl Frieden group's data from hydrogen—deuterium exchange coupled to mass spectrometry (HDX-MS) experiments—unveiled that all peptides that behaved differently between ApoE3 and ApoE4 (except 148–159) are close in proximity to residue 112, where the single-residue substitution is, providing a more straightforward explanation of isoform structural difference between ApoE3 and E4 ([Frieden et al., 2017](#)). It is quite interesting that the major difference between full-length ApoE3 and ApoE4 that Frieden et al. observed appear to be in peptides 27–37, 60–64, and 102–108, which surprisingly are all in the N-terminal helix bundle. These observations were all performed at 10 μM, conditions in which the protein is in tetrameric form ([Garai et al., 2011](#)). Thus, part of the signal might result from oligomeric interactions. Nonetheless, this difference in flexibility in those regions may account for the distinct preference of ApoE4 to plasma VLDL because of the curvature accommodation. Whether this is relevant to lipid binding in HDL-like particles in the CNS is not clear. The Frieden group also completed the ApoE lipid binding model concluding with a discussion of isoform differences ([Frieden et al., 2017](#)). They postulated that there is a domain-domain separation between N- and C-terminal domains as the first step in lipid binding, where charged lipid molecules replace and break the original salt bridges. This finalized model is consistent with the structural differences between ApoE3 and ApoE4 and also succeeded in explaining the difference in receptor binding between lipidated ApoE and non-lipidated ApoE due to the opening up of the C-terminal domain, which is required for accessing the LDLR binding site on the shielded N-terminal domain. Indeed, it is possible that the Weisgraber model still matches with the situation where ApoE gets fully lipidated and adopts an extended helical

conformation. However, experimental data are lacking to answer whether molecular structures of ApoE2 and ApoE4 fit with Wang and Frieden's model or whether ApoE2 and ApoE4 in fact adopt different conformations, leading to a mystery whether these two single-residue substitutions could induce non-trivial conformational changes that might alter the current model. It is also unknown whether ApoE2 and ApoE4 would undergo the same lipidation process or have different steps of conformational changes as suggested previously ([Morrow et al., 2002](#)). In addition, fluorescent measurements of ApoE lipid binding suggested that ApoE4 has a more disordered C-terminal domain, which lead to ApoE4's higher affinity for lipid and preferential association with plasma VLDL ([Saito et al., 2003](#)). This is opposite of Frieden's HDX results, yet, again, those experiments were performed at 10 $\mu$ M where ApoE is tetrameric. Nonetheless, there are some interesting results from molecular dynamic simulations that supported Wang and Frieden's model and provided pure computational models focusing on ApoE4 ([Ray et al., 2017](#); [Williams et al., 2015](#)). Importantly, none of the ApoE structures above were resolved in their native, physiological lipidated forms present *in vivo*. However, these structures indeed provide vital information for us to investigate the molecular features controlling folding, lipid interaction, and receptor binding of ApoE, whereas the empirical evidence supports aspects of these structural models to this day.

Early assessments of lipidated ApoE started with C-terminal fragments when the group of Robert J. Cushley managed to mimic the lipid environment of lipid-associated C-terminal regions of ApoE and ApoAI and restored their secondary structure by applying micelles of sodium dodecyl sulfate (SDS) or dodecylphosphocholine ([Shaw et al., 1997](#); [Wang et al., 1996a](#)). Further, Guangshun Wang and colleagues determined the first soluble structure of the partial ApoE C-terminal domain by CD spectra and 2D NMR ([Wang et al., 1996b](#)). The structure of both constructs demonstrated that the C-terminal domain of ApoE mostly forms helical structures in the lipid-associated environments, while it collapses into random structures in the absence of SDS, according to the CD spectra results. Although previous helical wheel projections had already led to a prediction that the C-terminal domain of ApoE forms an atypical class of helix called G amphipathic helix ([Segrest et al., 1992](#); [Sparrow et al., 1992](#)), it was shown for the first time that the C-terminal domain would fold into such an amphipathic helix, creating a hydrophobic gulf for DMPC interaction through Trp264, Phe265, Leu268, and Val269. While this domain is not folded in an ideal way—Val269 was not in the hydrophobic face in construct 267–289, the NMR structures confirmed that Trp276 is vital for lipid-association as its side chain is consistently motion-restricted due to its insertion into the micelle interior ([Wang et al., 1996b](#)). However, such a lipidated form of ApoE was restricted to only ~22 amino acids in the C-

terminal domain, leaving it still unclear as to how full-length ApoE present in a lipoprotein particle behaves.

To further address this question, the first and sole structure of lipidated ApoE was determined by Karl Weisgraber's group in 2006 via X-ray crystallography ([Peters-Libeu et al., 2006](#)). They crystallized ApoE4 with dipalmitoylphosphatidylcholine (DPPC) and analyzed the unique diffuse scattering pattern in their diffraction data. Surprisingly, the crystallized ApoE4-DPPC particle did not fall into a lipid bilayer with phospholipid molecules as previous suggested ([Raussens et al., 1998](#)). Rather, ApoE4-DPPC formed a spheroidal shape without a complete ring of diffuse scattering centered on 4.2Å, which was supported by the non-crystallographic 2-fold rotation axis ([Peters-Libeu et al., 2006](#)). Indeed, it is most likely that ApoE could have flexibility to accommodate different shapes and sizes of the lipoprotein particles since other methods showed that ApoE particles could form disc-like shapes with different concentrations of cholate and lipid, similar to the discoidal ApoE particles secreted by astrocytes ([DeMattos et al., 2001](#); [Hatters et al., 2009](#); [Mahley et al., 2009](#)). Alternatively, the spheroidal shape of the particles might be more favorable for the molecular packing under the crystallization condition they optimized. Both forms of ApoE lipoprotein particles could exist in different physiological environments. Their final model suggested a stoichiometry of two ApoE4 molecules per particle, each bending into a horseshoe-like shape, circumscribed around the lipid spheroid with a circular cross-section in the equatorial plane as a dimer ([Figures 3B and 3C](#)) ([Peters-Libeu et al., 2006](#)). One question that remains open is whether the structural properties of ApoE when bound to ApoE-lipid particles depend on the stoichiometry of ApoE per ApoE-lipid particle or is intrinsic to the protein. Although the overall resolution of this dataset was limited at 10Å, the height and width of the density map does fit with a side-by-side pair of helices model. It suggests that the ApoE protein backbone can possess some short helices and connecting loops (or bends) to form the semicircular arc and match with the curvature of a lipoprotein particle surface ([Figures 3B and 3C](#)). Upon ApoE lipidation, the Weisgraber group hypothesized that there are three steps: (1) the N-terminal four helix bundle stretches out and exposes its hydrophobic core, while the C-terminal domain dissociates from the original compact conformation; (2) the N-terminal domain further opens up and extends into a line where C-terminal domain in an anti-parallel fashion sits on top of the hydrophobic residues exposed on N-terminal helices and together forms a belt-like configuration, but, unlike the naive belt model, hydrophobic residues were thought to contribute to hairpin interactions between two helices, instead of interacting with lipid tails; (3) two ApoE "belts" eventually dimerize on the edge of the spheroidal shaped lipid core with a stagger angle at  $\sim 42^\circ$ , in which the each ApoE protein stabilizes the lipoprotein particle by enveloping half of the polar phospholipid head groups ([Figures 3B and 3C](#)) ([Peters-Libeu et al., 2006](#)).

Figures 3A–3D) (Peters-Libeu et al., 2006; Hatters et al., 2006). The Weisgraber model also explains how esterified cholesterol is incorporated into the HDL core as the ApoE horseshoe dimer can provide enough flexibility to accommodate expansion of the size and the changes of the curvature. Yet, the Weisgraber model is based substantially on the crystal structures with the N-terminal truncated forms of the ApoE isoforms and full-length ApoE-DPPC structure was based on a prediction according to the low-resolution electron density map. (Hatters et al., 2006; Weisgraber, 1994). It is undeniable that the missing portion of ApoE protein might influence the conformations of the known motifs if even a single-residue substitution can make a huge impact on the protein structure and functionality. Without a higher-resolution structure, it remains unclear whether the details of this structure are correct.

Recently, a computational model of full-length, lipidated ApoE4 was presented by Henry et al. with support from cross-linking mass spectrometry (MS) data (Henry et al., 2018). They achieved a relatively homogeneous population of lipidated human recombinant ApoE4 by mixing ApoE4 and POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocoline) at a molar ratio of 1:110. After size-exclusion chromatography purification, they treated the ApoE4-containing lipid particle with an equimolar mixture of light DSS (sodium trimethylsilylpropanesulfonate) (DSS-H12) and heavy DSS (DSS-D12) to crosslink spatially nearby Lys residue pairs, from which the special information of adjacent secondary structures would be recorded by MS and applied for molecular dynamic simulations. Their data suggested that each monomeric ApoE4 may fold into two major configurations: (1) an open hairpin structure where the hairpin bends at N-terminal helices 3 and 4 in juxtaposition to the C-terminal domain; (2) a compact hairpin that adopted a previously proposed N-terminal four helix bundle (Figure 3E). Then two ApoE4 monomers dimerize into either head-to-head or head-to-tail conformations wrapping around the edge of POPC lipid-disc, protecting the hydrophobic surface of packed POPC tails. Their molecular dynamics simulation indicated that ApoE4 secondary structures could stretch or shrink between helices or bend to accommodate the size changes of different lipoprotein particles. Interestingly, their data also suggested that the end of N-terminal helix 4 could change from original random coil to an  $\alpha$ -helical conformation with the existence of POPC disc and caused reorientation of Arg172—a previously reported key residue involved in ApoE-LDLR interaction—but is not in the LDLR binding site (Morrow et al., 2000). However, because DSS conjugation only applies for Lys pairs, helices without Lys residues such as helix 1 on the N-terminal domain could not be applied to their crosslinking MS (XL-MS) method. In addition, in the view of multiple configurations of ApoE protein on the lipid-containing particles, their XL-MS results would result from an ensemble of all the ApoE molecules after the DSS treatment, instead of only one or two conformations. Although the authors (1)




distinguished two different conformations of ApoE4 on the lipid-containing particles to satisfy the XL-MS data and (2) applied a reasonable initial model for simulation based on previous literature, it is still possible that these two structural models may not be able to completely represent the true nature of native ApoE lipoprotein particles. Moreover, the helical bundle presented both in their open hairpin and compact hairpin models was not clearly observed in their and in other groups initial cryoelectron microscopy (cryo-EM) images ([Henry et al., 2018](#); [Zhang et al., 2010](#)). Additionally, some of the XL-MS Lys pairs might come from less lipidated ApoE particles or even delipidated ones, which was not considered in the simulation. Nevertheless, their model raises the question of whether ApoE has different conformations on lipid nanodiscs and whether such differences result from interchangeable, but distinguishable, folding/unfolding steps or instead reflects a broader conformational heterogeneity of the protein. It is also unknown as to whether what they observed from ApoE4 could be applied to the other two isoforms or explain the isoform differences for AD pathology in a novel way.

In addition to these hallmark structures of the ApoE molecule, there are many other structural determinations worth mentioning that provide vital supplementary information for our understanding of ApoE and related interactions. For example, Guttman et al. characterized interactions between ApoE and LRP1 by solving the complex structure of ApoE fragment (130–149) fused with one conserved complement repeat (CR17) from LRP1 by NMR ([Guttman et al., 2010](#)). Their model suggests a universal mechanism for how CR-containing receptors such as LRP1 and LDLR interact, presumably through a side chain of tryptophan and some acidic residues surrounding one calcium ion to attract the Lys143 and Lys146 on the ApoE helix. The interaction between ApoE and heparin has been determined in 2001, showing that Arg142 and Arg145 are critical to the 6-Osulfo group of glucosamine ([Dong et al., 2001](#)). Ren's group also pioneered the possibility of applying novel techniques such as cryo-EM in lipoprotein structure determination, including ApoE ([Zhang et al., 2010, 2013](#)). Going forward, the use of cryo-EM to obtain high-resolution structural features may ultimately prove to be critical in determining the structure of lipidated forms of ApoE produced by different cell types to answer some of these unresolved issues.

## Physiological Form of ApoE and Neuropathology

In its native form, ApoE is secreted as HDL-like lipoprotein particles in the CNS ([Figure 4A](#)). This alters its ability to bind ApoE receptors and its interactions with pathological proteins, such as A $\beta$  ([Garai et al., 2014](#); [Strittmatter et al., 1993b](#)) as well as structures such as normal and damaged synapses. The lipidation status of ApoE has also been postulated to contribute to the progression of AD as the size and components of ApoE-containing lipoproteins have

been associated with disease progression in AD ([Grimm et al., 2017](#)). The lipidation process of ApoE *in vivo* is not well understood, nor is the conformation of lipidated ApoE. As discussed, only two structural models of lipidated recombinant ApoE have been assessed ([Hatters et al., 2006](#); [Henry et al., 2018](#)). While the crystal structure has unveiled a single, low-resolution model of lipidated ApoE on a spherical DPPC lipid-containing particle, the later computational model assumes ApoE is bound to a discoidal lipoparticle. Both structural models suggest that two ApoE molecules form a dimeric ring to stabilize lipids in the center in its final state, while the lipoprotein particle might be disc-shaped or spheroidal, depending on certain lipidation conditions. However, neither of those two structures could provide detailed information of the molecular configurations of ApoE protein on the lipid-containing particle at even near-atomic resolution, which has limited our understanding of characteristics of native ApoE *in vivo*.



#### Figure 4. Model of ApoE and Where It May Impact AD Neuropathology

- (A) Lipidated ApoE is secreted primarily by astrocytes in the CNS.
- (B) Microglia secrete ApoE in disease conditions and microglial ApoE can be integrated into existing amyloid- $\beta$  plaques.
- (C) ApoE is uptaken by LDLR present on astrocytes and other cell types, such as endothelial cells (see D) and neurons (see E).
- (D) Amyloid- $\beta$  and lipidated ApoE may compete for clearance by binding to LDLR receptors. ApoE might also form complexes with amyloid- $\beta$  which may promote clearance of amyloid- $\beta$ .
- (E) ApoE is uptaken by neurons through receptors such as LDLR, LRP1, and HSPG.
- (F) Recycling endosomes or lysosomes in neurons are potential sites where non-lipidated or partially lipidated ApoE interacts with amyloid- $\beta$  inducing amyloid- $\beta$  fibrillization.
- (G) ApoE in plaques is presumably required for microglial clustering around amyloid- $\beta$  plaques.
- (H) ApoE may promote the engulfment of dying or damaged synapses/neurons with fibrillar tau accumulation.

---

Moreover, more subtle isoform-specific size differences are also observed in the CNS. Observational studies of lipoprotein particle size in human CSF showed that ApoE4 was present in smaller HDL-like particles, whereas ApoE2 was associated with larger HDL-like particles ([Heinsinger et al., 2016](#)). In mouse models expressing different human ApoE isoforms, ApoE4 expression results in smaller particles, while ApoE2 forms larger particles compared to ApoE3 ([Hu et al., 2015](#)). Consistency in the size preference between ApoE isoforms across species indicates that these differences are independent from the human/mouse brain environment. Rather these preferences result from intrinsic properties of the ApoE protein. This is supported by experiments using hydrogen-deuterium exchange coupled to MS experiments that showed that ApoE4 was more flexible at several residues (27–37, 60–64, and 102–108) than ApoE3, which may explain the prevalence of ApoE4 in VLDL ([Frieden et al., 2017](#)). Isoform-specific differences may due to the ability of the N-terminal and C-terminal domains to separate. However, it is still not clear how and why ApoE is present as discoidal particles secreted by astrocytes ([Fagan et al., 2002](#)). This may be driven by the ability of ApoE to become lipidated in the CNS, which is a property both of the

protein glycosylation and secretory apparatus of particular cell types. The lipidation of ApoE lipoparticles in the CNS may have a strong association with AD pathology. It has been found that the lipid efflux protein ABCA1 is required for ApoE to become lipidated by astrocytes ( [Hirsch-Reinshagen et al., 2004](#); [Wahrle et al., 2004](#)). Further, the lack of ABCA1 in A $\beta$ -depositing mice results in increased amyloidosis, while overexpression of ABCA1 increases ApoE-lipidation in the brain and decreases amyloidosis ( [Hirsch-Reinshagen et al., 2005](#); [Koldamova et al., 2005](#); [Wahrle et al., 2005, 2008](#)). In addition, LXR agonists, which increase ABCA1, among other effects, have been shown to reduce A $\beta$  pathology in mice ( [Fitz et al., 2010](#)). However, current studies do not suggest isoform-specific differences in ABCA1 binding, nor describe the ultimate lipidation states after interacting with ABCA1 ( [Krimbou et al., 2004](#)). Nonetheless, these studies suggest that the degree of ApoE lipidation influences its effect on A $\beta$  even though the impact on the conformation of ApoE is not completely understood.

The lipidation of ApoE and isoform-specific differences in stability may further contribute to differences in AD neuropathogenesis. The overall protein stability and lipid binding preferences appear to be linked. This is predicted to be driven by interactions between the N-terminal and C-terminal domains ( [Hatters et al., 2005](#); [Xu et al., 2004](#)). This was supported by a mutagenesis study where mutation of Glu255 to Ala255 altered the lipid binding preference of ApoE4 from plasma VLDL to HDL, similar to ApoE3 and ApoE2 ( [Weisgraber, 1990](#)). Meanwhile, ApoE lipidation and its impact on AD pathology may be linked with secretion by different cell types. For example, while astrocytes produce and secrete most of the ApoE containing HDL-like lipoproteins in the normal CNS, following CNS damage and in the setting of neurodegeneration, microglia strongly upregulate ApoE levels ( [Krasemann et al., 2017](#)). The function of ApoE produced by microglia has been proposed to be involved in the microglial activation response ( [Krasemann et al., 2017](#)). It has recently been shown the microglia secrete ApoE in very poorly lipidated lipid particle as compared to astrocytes ( [Huynh et al., 2019](#)). This is of particular interest as the deposition of ApoE into A $\beta$  plaques appears to be driven primarily by ApoE produced from microglia ( [Parhizkar et al., 2019](#)) ( [Figure 4B](#)). It has also been reported that neurons may upregulate ApoE in disease conditions; in the context of ApoE4, this may result in neurotoxicity ( [Mahley and Huang, 2012](#)). Moreover, it has been reported that the overexpression of ApoE4 from astrocytes is neuroprotective, while the overexpression of ApoE4 by neurons is not ( [Buttini et al., 2010](#)). Whether there is a unique lipidation status and conformation of ApoE produced in neurons is currently unknown. Further research is needed to better understand the conformation of ApoE on differentially lipidated lipoprotein particles and how such differences influence ApoE structure and the effect of ApoE on AD neuropathology, both in an isoform-specific and cell-specific manner.

## ApoE Receptors and Neuropathology

In 1970s, it was found that ApoE was a primary ligand for LDLR ([Figure 4C](#)) and that ApoE2 was involved in familial type III hyperlipoproteinemia due to the dramatic reduction in binding to LDLR ([Innerarity and Mahley, 1978](#); [Innerarity et al., 1979](#); [Wardell et al., 1982](#); [Weisgraber et al., 1982](#)). A classic theory suggested that the interaction between ApoE and LDLR was dependent on the arrangement of salt bridges in the LDLR binding site of ApoE ([Dong and Weisgraber, 1996](#)). However, the full-length structure of ApoE3 shows that the C-terminal domain potentially shields the LDLR receptor binding region that was assumed to be exposed in the Weisgraber model ([Chen et al., 2011](#)). Certainly, once ApoE is lipidated, the salt bridges between Arg150 and Asp154 may exist in the fully extended helical conformation of lipidated ApoE2. Therefore, it remains an important question as to whether the impact of Cys158 on ApoE-LDLR binding is due to its effect on the initial lipid binding stage of ApoE leading to an inability to adopt a specific conformation on the lipid surface in order to bind LDLR or whether it is due to salt-bridge rearrangement on lipidated ApoE that was predicted based on the structure of the N terminus. As such, lipidation of ApoE is indispensable to understand ApoE's ability to bind to LDLR. This interaction may be especially important as ApoE2 shows a dramatic reduction in the ability to bind LDLR and decreases AD risk ([Innerarity et al., 1984](#); [Lalazar et al., 1988](#)).

In fact, the lipidation state of ApoE and interactions with the C-terminal domain were known from early on to play a critical role in the binding of ApoE to LDLR. ApoE2 bound to DPMC has <1% binding activity to LDLR as does plasma VLDL isolated from subjects with ApoE2/2 genotype ([Innerarity et al., 1984](#)). However, the N-terminal fragment of ApoE2 has 12-fold greater binding to LDLR, and Cys modification with cysteamine and binding to DPMC restores its binding activity to that of ApoE3-DPMC ([Innerarity et al., 1984](#)). This strongly suggests that the reduction in ApoE2 binding to LDLR is due to conformational changes only present in the full-length lipidated structure of ApoE2. Fluorescence resonance energy transfer (FRET) studies have investigated the conformational changes that occur when ApoE binds to lipid, with these studies suggesting that N-terminal domain of ApoE adopts an open conformation upon lipid binding ([Fisher et al., 2000](#)). These results are further supported by an assay using soluble LDLR where only lipidated full-length ApoE3 was found to bind LDLR compared to lipid-free ApoE3 ([Yamamoto et al., 2008](#)). Lipidation of ApoE is also critical to expose this N-terminal region to LDLR as the C-terminal domain shields this region based on the NMR full-length ApoE3 structure ([Chen et al., 2011](#)). The exposure of the LDLR binding site may be further regulated by the conformation of ApoE on lipoprotein particles. It has been proposed that there are two different major conformations

of ApoE that co-exist—open hairpin and compact hairpin—which may undergo different lipidation processes ([Henry et al., 2018](#)).

Answering this question of how ApoE isoform and lipidation affect receptor binding is critical to understanding the impact of ApoE on processes related to neurodegeneration. ApoE is known to bind to LDLR, LRP1, and other receptors that are LDLR family members ([Holtzman et al., 2012](#)). This is highlighted not only by the differential risk for late-onset AD conferred by ApoE4 > ApoE3 > ApoE2 but also by the recent data from an individual with autosomal-dominant AD who is also homozygous for ApoE3 with the Christchurch mutation (R136S). This individual has a strongly delayed onset of cognitive decline and tau-related pathology ([Arboleda-Velasquez et al., 2019](#)). The Christchurch mutation on ApoE3 leads to strongly decreased LDLR binding and also decreased binding to heparin ([Lalazar et al., 1988](#); [Arboleda-Velasquez et al., 2019](#)). On the other hand, ApoE4 binds to heparin sulfate and dermatan sulfate more strongly than ApoE2 and ApoE3 as measured by surface plasmon resonance (SPR) ([Yamauchi et al., 2008](#)). The binding constants of ApoE-heparin binding also differ among isoforms ([Futamura et al., 2005](#)). These results are interesting in light of the fact that the individual had autosomal dominant AD but had delayed dementia despite having a lot of amyloid deposition in the brain, and had much less tau pathology and neurodegeneration than would be expected ([Arboleda-Velasquez et al., 2019](#)). As data in a mouse model of tauopathy show that ApoE strongly increases not only tauopathy but tau-mediated neurodegeneration via microglia ([Shi et al., 2017, 2019](#)), perhaps ApoE binding to heparin linked with other receptors on microglia is important in this process. The related structures and interactions that mediate these types of effects are completely unknown.

Likely as a consequence of receptor binding, the ApoE isoform is known to affect the amount of ApoE in the CNS. ApoE4 has the lowest protein levels and ApoE2 has the highest protein levels ([Bales et al., 2009](#); [Huyh et al., 2019](#)). Since the binding of ApoE2 to LDLR is dramatically reduced, these data suggest that the protein levels of ApoE in the CNS are a direct consequence of the ability of ApoE to bind LDLR. Global knockout of LDLR significantly increased ApoE4 and ApoE3 levels while not affecting ApoE2 levels ([Fryer et al., 2005](#)). This is of particular interest as not only the isoform but also the levels of ApoE determine the amount of A $\beta$  deposition that develops in the brain ([Bien-Ly et al., 2012](#); [Kim et al., 2011](#)). In fact, it has been suggested that ApoE and A $\beta$  compete for the same receptors for clearance ([Kanekiyo et al., 2013](#); [Verghese et al., 2013](#)) ([Figure 4D](#)). Further, LDLR has been demonstrated to directly bind A $\beta$ , contributing to cellular uptake of A $\beta$  ([Basak et al., 2012](#)), although the exact binding site is still unknown. Interestingly, overexpression of LDLR leads to a reduction in A $\beta$  pathology ([Kim et al., 2009](#)). Similarly,

knockout of LRP1 in astrocytes also leads to greater accumulation of A $\beta$  pathology ([Liu et al., 2017](#)) ([Figure 4E](#)). However, these effects appear to be cell type dependent as knockout of LRP1 in neurons decreased A $\beta$  pathology in APPPS1/ApoE4 mice back to the levels seen in ApoE3/APPPS1 mice ([Tachibana et al., 2019](#)). These results may be neuron specific as neuronal synapses are postulated to be a site of ApoE-A $\beta$  interaction that initiates A $\beta$  aggregation ([Bilousova et al., 2019](#)) ([Figure 4F](#))

## ApoE and A $\beta$ Fibrillization: Consequences for Neuropathology

Due to the strong association of ApoE isoform with AD risk and the presence of ApoE in A $\beta$  plaques, there has been much interest in the biochemical interaction between ApoE and A $\beta$ . Early studies using plasma purified, but de-lipidated ApoE, found that ApoE4 binds to A $\beta$  more quickly than ApoE3 ([Strittmatter et al., 1993b](#)). These initial findings were supported by studies where it was found that de-lipidated ApoE4 isolated from human plasma associated more rapidly with A $\beta$  than ApoE3 and formed a denser matrix of monofibrils than from co-incubation of ApoE3 with A $\beta$  ([Sanan et al., 1994](#)). In both cases, immunogold labeling showed ApoE uniformly distributed across the surface of A $\beta$  monofibrils. Using a thioflavin-T assay, ApoE was found to increase the rate of A $\beta$  fibrillogenesis and total amount of fibrillar A $\beta$  ([Castaño et al., 1995](#)). In contrast, using lipidated ApoE showed a different trend where ApoE2 was found to associate most strongly with A $\beta$  peptide followed by ApoE3 then by ApoE4 ([Aleshkov et al., 1997](#)). It was also found using lipidated ApoE that ApoE3 rather than ApoE4 formed more SDS-stable complexes with A $\beta$  ([LaDu et al., 1994, 1995](#)). Together these findings began to demonstrate that the binding mechanism of ApoE to A $\beta$  is dependent on differences in the conformation of non-lipidated ApoE and lipidated ApoE ([Aleshkov et al., 1997](#)). Moreover, there might also be a thermal and chemical stability tier in the order ApoE4 < ApoE3 < ApoE2 with the support of reducing folding intermediate data from ApoE4 to ApoE3 to ApoE2. Such a difference in stability was also considered to affect the ApoE-A $\beta$  interaction ([Segrest et al., 1992](#)). The less stable ApoE4 is also thought to adopt a more molten-globule-like conformation with A $\beta$ -bound that may break down the lysosomal membrane ([Ji et al., 2002, 2006](#)).

More studies have been undertaken in order to try to understand the impact of ApoE on the aggregation of A $\beta$  with new techniques. Studies looking at how ApoE influences the rate of A $\beta$  aggregation have found that ApoE actually slows A $\beta$  aggregation ([Garai et al., 2014](#); [Raulin et al., 2019](#)). Non-lipidated ApoE4 was found to slow aggregation the most compared to ApoE3 and ApoE2 slowed aggregation the least. These experiments were carried out with ApoE concentrations of 100  $\mu$ M where ApoE is likely oligomeric. However, DMPC-lipidated ApoE showed the same trend with ApoE4-DMPC slowing A $\beta$  aggregation more than ApoE2



and ApoE3. ApoE derived from astrocytes also slowed A $\beta$  aggregation but did not show an isoform-specific difference, highlighting the importance of the lipid environment in understanding ApoE-A $\beta$  interaction ([Figures 4G and 4H](#)). However, these studies do not completely address the pathological consequences of ApoE on A $\beta$  aggregation, due to the known association of ApoE with A $\beta$  plaques *in vivo*. ApoE isoforms show differences in the rate of self-assembly and in their propensity to form fibrillar structures. Whether such fibrillization occurs *in vivo* is not clear, yet, *in vitro*, ApoE4 was found to rapidly self-associate and form fibrils faster than ApoE3; ApoE2 showed the slowest rate of self-aggregation and fibrillization ([Raulin et al., 2019](#)). On the other hand, a study applying fluorescence cross-correlation spectroscopy (FCCS) combined with alternating laser excitation (ALEX) characterized this interaction in solution, overcoming the immobilization restraint in SPR and noise signal from self-association in an electron paramagnetic resonance assay ([Ly et al., 2013](#)). Their data clearly suggest that A $\beta$  oligomers bind to ApoE4 slower than ApoE3, where both interactions prevented A $\beta$  aggregation by itself. Further, the ApoE-A $\beta$  complex showed limited dissociation, indicating a much tighter complex molecule formed, which was consistent with the SDS-resistant feature reported previously ([Bentley et al., 2002](#); [LaDu et al., 1994](#)). The delay of A $\beta$  aggregation by ApoE binding has been further demonstrated by FRET recently ([Ghosh et al., 2019](#)). However, the new data still led to a conclusion, not observed *in vivo*, that ApoE4 binds faster than ApoE3 and is more efficient in preventing A $\beta$  aggregation. Also, full-length ApoE has a higher-affinity binding to A $\beta$  comparing with either the N- or C-terminal domains. Meanwhile, DMPC-associated ApoE4 seemed to fail to prevent A $\beta$  aggregation but DMPC-associated ApoE3 retained that ability in this study, which is contradictory compared to earlier results ([Garai et al., 2014](#); [Raulin et al., 2019](#)). Indeed, lipidated ApoE seems to behave much differently from non-lipidated ApoE in its interaction with A $\beta$ . Presumably, the interaction between A $\beta$  and ApoE will substantially and kinetically depend on the lipidation state of ApoE.

Domain studies of ApoE-A $\beta$  binding also yielded different conclusions. Some early studies on the interaction of ApoE and A $\beta$  revealed that the lipid binding region of ApoE (244–272) is critical for ApoE-A $\beta$  binding ([Strittmatter et al., 1993b](#)). This is further supported by the full-length NMR model of ApoE3, where the ApoE C-terminal domain contains multiple hydrophobic residues that are hypothesized to initiate A $\beta$  binding. Although, other studies have also identified residues in the NT domain to be involved ([Winkler et al., 1999](#)). This suggests that A $\beta$  may compete with ApoE-containing lipoproteins for binding to LDLR and may also explain differences in ApoE isoform affinity for A $\beta$  that is dependent on the lipidation state of ApoE. A recent study found that N- and C-terminal domains and full-length ApoE may have similar binding affinity at sub-micromolar range (where ApoE monomeric and dimeric forms are prevalent) to A $\beta$  fibrils ([Gunzburg et al., 2007](#)). Their FRET

results suggested that the ApoE N-terminal domain could undergo similar conformational changes to adapt the binding to different amyloid fibril structures such as ApoC-II fibrils and A $\beta$  fibrils. Interestingly, R90, C112, and R119 were predicted to interact with E22 on the A $\beta$  fibril, where C112 is the key residue to distinguish ApoE2 from ApoE3 and ApoE4.

While the true biochemical interactions between ApoE and A $\beta$  are still under debate, *in vivo*, it is possible that ApoE has two distinct impacts on A $\beta$  pathology depending on its state. The impact of ApoE isoform on A $\beta$  pathology is dramatic in humans and animal models and is one of the best-studied consequences of ApoE on AD pathology ([Morris et al., 2010](#); [Reiman et al., 2009](#)). Expression of human ApoE in various mouse models of AD-like A $\beta$  amyloidosis has found significant isoform dependent effects where ApoE4 increases the amount of A $\beta$  plaques and ApoE2 decreases the amount of A $\beta$  pathology relative to ApoE3 ([Bales et al., 2009](#); [Holtzman et al., 2000](#); [Huynh et al., 2017, 2019](#); [Liu et al., 2017](#)). There is a lot of evidence that ApoE influences A $\beta$  accumulation via effects on A $\beta$  clearance and seeding. In addition, one study reported that ApoE directly altered A $\beta$  production in embryonic stem cell-derived neurons ([Huang et al., 2017](#)). Studies using either antisense oligonucleotides to decrease ApoE or tamoxifen-inducible expression to increase ApoE have shown that the impact of ApoE isoform on A $\beta$  pathology is time dependent ([Huynh et al., 2017](#); [Liu et al., 2017](#)). Reduction of ApoE early prior to the onset of A $\beta$  deposition reduces the amount of A $\beta$  pathology, while reduction after the initial seeding stage of amyloid pathology had no major effect ([Huynh et al., 2017](#)). Similarly, induction of ApoE4 expression before A $\beta$  deposition increases A $\beta$  pathology, but when done after A $\beta$  deposition there was no effect ([Liu et al., 2017](#)). Together, these results suggest that the early stage of A $\beta$  pathology where A $\beta$  first misfolds into a  $\beta$ -pleated sheet and starts to form plaques (i.e. “seeding”) is impacted by ApoE isoform. In fact, knockout of ApoE results in a huge reduction of A $\beta$  fibril formation into the  $\beta$ -pleated sheet structures in amyloid plaques ([Bales et al., 1999](#); [Holtzman et al., 2000](#); [Ulrich et al., 2018](#)). Furthermore, the presence of ApoE in plaques affects the microglial response to A $\beta$  plaques and may ultimately impact tau-mediated neurodegeneration ([Shi et al., 2017](#); [Ulrich et al., 2018](#)) ([Figure 4I](#)). Lipidated ApoE likely competes for clearance with A $\beta$  and its impact on pathology is driven by isoform-specific differences in receptor binding. In contrast, the self-association and aggregation of ApoE may promote the formation/seeding of A $\beta$  plaques and also be involved in A $\beta$  pathology in an isoform-specific manner. Interestingly, some hydrophobic residues (Phe257, Phe265, Trp276, Val283, Leu279, Val287) in the C-terminal domain of ApoE remain solvent exposed and might form a strong hydrophobic pocket, which may contribute to initial lipid binding ([Frieden et al., 2017](#)) (PDB: [2I7p](#) ↗). Such a hydrophobic surface may also explain how ApoE can attract the A $\beta$  peptide and eventually incorporate into the dense core of amyloid plaques in an aggregated form ([Liao et al., 2018](#)). Also, the interaction of ApoE

and A $\beta$  may be mediated by cleavage of the ApoE protein as an increased number of N-terminal ApoE fragments have been reported in ApoE4 plaques ([Jones et al., 2011](#)). On the other hand, A $\beta$  has numerous biophysical forms that might potentially interact with ApoE ([Frieden et al., 2017](#)). It is still not clear as to which form or forms of ApoE initiate and propagate ApoE-A $\beta$  interactions that contribute to pathology. This highlights the importance of knowing the structure of different forms of ApoE.

It is challenging to analyze and interpret biochemical data addressing interactions between ApoE and A $\beta$  due to the self-association of each molecule. Non-lipidated ApoE exists in at least three forms—monomer, dimer, and tetramer—sometimes with higher-order oligomeric forms. Further, A $\beta$  is known to strongly self-aggregate under specific conditions. To date, it is still unclear when and how the interaction between ApoE and A $\beta$  occurs, although ApoE has been observed in amyloid plaques for years. Since ApoE is secreted in a lipidated form *in vivo* and a non-lipidated or poorly lipidated form of ApoE is observed in A $\beta$  plaques ([Liao et al., 2018](#)), one hypothesis is that the interaction of A $\beta$  starts with lipidated ApoE and the ApoE found in plaques is in a specific conformation resulting from its partial or complete de-lipidation. The models of lipidated ApoE4 proposed by Weisgraber or Wang/Frieden both suggest that residues in the C-terminal domain of ApoE are bound to phospholipid, and it is possible that A $\beta$  binding to this site may result in de-lipidation of ApoE. Indeed, using ELISA to measure soluble ApoE-A $\beta$  complexes, it was found that lower levels of ApoE-A $\beta$  soluble complexes were detectable in hippocampal homogenates from ApoE4-expressing mice compared to ApoE2 and ApoE3-expressing mice ([Tai et al., 2013](#)). This may explain earlier results where ApoE binding was measured by examining SDS-stable complexes that likely represent complexes of aggregated ApoE-A $\beta$  ([Strittmatter et al., 1993b](#)). Additionally, soluble A $\beta$  oligomers in the brain were higher in ApoE4 carriers compared to ApoE3 with ApoE2 having the lowest levels ([Hashimoto et al., 2012](#)).

Of importance in future work will be to characterize (1) how different lipidation states of ApoE influence its structure and ability regulate its ability to bind A $\beta$ , (2) whether ApoE-A $\beta$  affects the binding of ApoE to the lipoprotein and its structural conformation, (3) whether ApoE-A $\beta$  interaction occurs prior to or is concomitant with amyloid fibrillization, (4) whether this interaction leads to or prevents fibrillization of A $\beta$  or even plaque formation, and (5) molecular details from future structural determinations of complex between lipidated and non-lipidated ApoE and monomeric versus oligomeric A $\beta$ .

## Conclusions

ApoE plays a critical role in the pathogenesis of several neurodegenerative diseases, including its dramatic impact on AD risk. Resolving the molecular function and interactions of ApoE under physiological conditions and in the setting of disease will be critical to understanding disease pathogenesis but also in designing therapeutics to combat these diseases. Our current understanding of the role of ApoE in these diseases is limited by incomplete structural information. ApoE2 and ApoE4 differ from ApoE3 by a single amino acid substitution, which results in dramatically different impacts on disease risk and outcomes. Changes in the interaction of ApoE with its receptors or with proteins involved in disease pathogenesis are correlated with either slowing down or accelerating disease progression. In addition, ApoE has been shown to directly interact with A $\beta$ , tau, and  $\alpha$ -synuclein, likely directly contributing to the formation of protein aggregates or the response of the brain to these aggregates in various diseases ([Davis et al., 2020](#); [Strittmatter et al., 1993a](#); [Zhao et al., 2018, 2020](#)). The molecular details of these interactions have not yet been elucidated, impeding progress in the development of effective therapeutics targeting these interactions. To advance our understanding of ApoE and its role in AD, diseases of the CNS, and in normal physiology, it is also essential to solve, at high-resolution, structure of lipidated ApoE in the CNS—its physiological form. Lipidation of ApoE and the conformational change that occurs in ApoE on the lipid surface is required for binding of ApoE to ApoE receptors that are members of the LDLR family. In addition, interdomain interactions within ApoE may drive isoform-specific differences in the binding of ApoE to its receptors, lipids, and pathological proteins, such as A $\beta$ . Moreover, some biochemical results indicated that non-lipidated ApoE undergoes dimerization and then tetramerization at high concentration, while the model that monomeric ApoE binds to lipids fit best with binding curves ([Frieden et al., 2017](#); [Garai et al., 2011](#)). Current methods are insufficient for elucidating these interactions within ApoE. However, solving isoform-specific structures of non-lipidated ApoE and lipidated ApoE complex both alone and with the binding partners would allow for the design of drugs to directly modulate ApoE-receptor and ApoE-protein interactions at a molecular level. Moreover, structure correctors also showed some potential to alleviate toxic effects from ApoE4 ([Wang et al., 2018](#)). Indeed, there are current studies that postulate modulating the structure of ApoE4 can reverse its negative effects on A $\beta$  pathology, but we currently lack methodologies to confirm the occurrence and extent of such modulations.

To summarize, our review has focused on the biology of ApoE that relates our evolving understanding of ApoE structure over the last 40 years to the pathophysiology of AD. Three structural models of ApoE have yielded insights that explain apparently contradictory observations in the molecular features and interactions of ApoE. Despite this, each model appears to explain some specific, but not all, aspects of the molecule. Although current

models of ApoE have managed to explain different functions and interactions of this molecule, we still lack critical experimental data that would complete the models, such as a full-length, high-resolution structure of ApoE2 and ApoE4, including all isoforms when lipidated. Even, the isoform-specific differences between non-lipidated forms of ApoE2, ApoE3, and ApoE4 have not been completely resolved. Further studies utilizing single-molecule FRET, or *in vivo* FRET, based on emerging models would be informative. Moreover, novel drug targets that might leverage ApoE or related interactions still await determination of ApoE-A $\beta$  and ApoE-receptor complexes. For example, the complex structure of a reported interaction between ApoE and TREM2 has never been determined ([Atagi et al., 2015](#)). As new structural models generate new hypotheses, future studies that apply emerging techniques such as small-molecule inhibitors of ApoE-receptor and ApoE-protein interactions, structure modulators, and cryo-EM will pave the way for therapeutic development for AD and other neurodegenerative diseases based on knowledge of the relationship between the structure and function of ApoE.

## Acknowledgments

This work was supported by NIH grants [NS090934](#) (D.M.H.), [AG047644](#) (D.M.H.), [AG062837](#) (A.S.), and [AG58518](#) (M.R.S.), NSF grant [DGE-1745038](#) (M.R.S.), the Cure Alzheimer's Fund (D.M.H.), JPB Foundation (D.M.H.), Ruth K. Broad Biomedical Research Foundation (A.S.), and the Alzheimer's Association (A.S.).

## Declaration of Interests

D.M.H. is listed as an inventor on a US patent application #20190270794 entitled “Anti-APOE antibodies” from Washington University. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali and consults for Genentech, Merck, and Idorsia. Washington University (D.M.H.) has a sponsored research agreement to work on apoE antibodies from NextCure. All other authors have no competing interests.

[Special issue articles](#)   [Recommended articles](#)

## References

[Aggerbeck et al., 1988](#) L.P. Aggerbeck, J.R. Wetterau, K.H. Weisgraber, R.W. Mahley, D.A. Agard  
Crystallization and preliminary X-ray diffraction studies on the amino-terminal (receptor-binding) domain of human apolipoprotein E3 from

## serum very low density lipoproteins

J. Mol. Biol., 202 (1988), pp. 179-181



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Aleshkov et al., 1997](#) S. Aleshkov, C.R. Abraham, V.I. Zannis

## Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. $\beta$

Biochemistry, 36 (1997), pp. 10571-10580

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Arboleda-Velasquez et al., 2019](#) J.F. Arboleda-Velasquez, F. Lopera, M. O'Hare, S. Delgado-Tirado, C.

Marino, N. Chmielewska, K.L. Saez-Torres, D. Amarnani, A.P. Schultz, R.A. Sperling, *et al.*

## Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report

Nat. Med., 25 (2019), pp. 1680-1683

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Atagi et al., 2015](#) Y. Atagi, C.-C. Liu, M.M. Painter, X.-F. Chen, C. Verbeeck, H. Zheng, X. Li, R.

Rademakers, S.S. Kang, H. Xu, *et al.*

## Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)

J. Biol. Chem., 290 (2015), pp. 26043-26050



[View PDF](#) [View article](#) [Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Baker et al., 1975](#) H.N. Baker, A.M. Gotto Jr., R.L. Jackson

## The primary structure of human plasma high density apolipoprotein glutamine I (ApoA-I). II. The amino acid sequence and alignment of cyanogen bromide fragments IV, III, and I

J. Biol. Chem., 250 (1975), pp. 2725-2738



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Bales et al., 1997](#) K.R. Bales, T. Verina, R.C. Dodel, Y. Du, L. Altstiel, M. Bender, P. Hyslop, E.M.

Johnstone, S.P. Little, D.J. Cummins, *et al.*


## Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition

Nat. Genet., 17 (1997), pp. 263-264

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Bales et al., 1999](#) K.R. Bales, T. Verina, D.J. Cummins, Y. Du, R.C. Dodel, J. Saura, C.E. Fishman, C.A. DeLong, P. Piccardo, V. Petegnief, *et al.*  
**Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease**  
Proc. Natl. Acad. Sci. USA, 96 (1999), pp. 15233-15238  
[View in Scopus ↗](#) [Google Scholar ↗](#)

[Bales et al., 2009](#) K.R. Bales, F. Liu, S. Wu, S. Lin, D. Koger, C. DeLong, J.C. Hansen, P.M. Sullivan, S.M. Paul  
**Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice.** $\beta$   
J. Neurosci., 29 (2009), pp. 6771-6779  
[View in Scopus ↗](#) [Google Scholar ↗](#)

[Basak et al., 2012](#) J.M. Basak, P.B. Verghese, H. Yoon, J. Kim, D.M. Holtzman  
**Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of A $\beta$  uptake and degradation by astrocytes.** $\beta$   
J. Biol. Chem., 287 (2012), pp. 13959-13971  
 [View PDF](#) [View article](#) [Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Bell et al., 2012](#) R.D. Bell, E.A. Winkler, I. Singh, A.P. Sagare, R. Deane, Z. Wu, D.M. Holtzman, C. Betsholtz, A. Armulik, J. Sallstrom, *et al.*  
**Apolipoprotein E controls cerebrovascular integrity via cyclophilin A**  
Nature, 485 (2012), pp. 512-516  
[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Bentley et al., 2002](#) N.M. Bentley, M.J. Ladu, C. Rajan, G.S. Getz, C.A. Reardon  
**Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges**  
Biochem. J., 366 (2002), pp. 273-279  
[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Bien-Ly et al., 2012](#) N. Bien-Ly, A.K. Gillespie, D. Walker, S.Y. Yoon, Y. Huang  
**Reducing human apolipoprotein E levels attenuates age-dependent A $\beta$  accumulation in mutant human amyloid precursor protein transgenic mice.**  
 $\beta$   
J. Neurosci., 32 (2012), pp. 4803-4811  
[View in Scopus ↗](#) [Google Scholar ↗](#)

[Bilousova et al., 2019](#) T. Bilousova, M. Melnik, E. Miyoshi, B.L. Gonzalez, W.W. Poon, H.V. Vinters, C.A. Miller, M.M. Corrada, C. Kawas, A. Hatami, *et al.*

**Apolipoprotein E/Amyloid- $\beta$  Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4. $\beta$**

Am. J. Pathol., 189 (2019), pp. 1621-1636

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Blue et al., 1983](#) M.L. Blue, D.L. Williams, S. Zucker, S.A. Khan, C.B. Blum

**Apolipoprotein E synthesis in human kidney, adrenal gland, and liver**

Proc. Natl. Acad. Sci. USA, 80 (1983), pp. 283-287

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Boyles et al., 1985](#) J.K. Boyles, R.E. Pitas, E. Wilson, R.W. Mahley, J.M. Taylor

**Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system**

J. Clin. Invest., 76 (1985), pp. 1501-1513

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Bradley et al., 1982](#) W.A. Bradley, E.B. Gilliam, A.M. Gotto Jr., S.H. Gianturco

**Apolipoprotein-E degradation in human very low density lipoproteins by plasma protease(s): chemical and biological consequences**

Biochem. Biophys. Res. Commun., 109 (1982), pp. 1360-1367

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Breiter et al., 1991](#) D.R. Breiter, M.R. Kanost, M.M. Benning, G. Wesenberg, J.H. Law, M.A. Wells, I. Rayment, H.M. Holden

**Molecular Structure of an Apolipoprotein Determined at 2.5-Å Resolution**

Biochemistry, 30 (1991), pp. 603-608

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Buttini et al., 2010](#) M. Buttini, E. Masliah, G.-Q. Yu, J.J. Palop, S. Chang, A. Bernardo, C. Lin, T. Wyss-Coray, Y. Huang, L. Mucke

**Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice**

Am. J. Pathol., 177 (2010), pp. 563-569

 [View PDF](#) [View article](#) [Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Cam et al., 2005](#) J.A. Cam, C.V. Zerbinatti, Y. Li, G. Bu



Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein. $\beta$

J. Biol. Chem., 280 (2005), pp. 15464-15470



[View PDF](#) [View article](#) [Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Cardin et al., 1991](#) A.D. Cardin, D.A. Demeter, H.J. Weintraub, R.L. Jackson

Molecular design and modeling of protein-heparin interactions

Methods Enzymol., 203 (1991), pp. 556-583



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Castaño et al., 1995](#) E.M. Castaño, F. Prelli, M. Pras, B. Frangione

Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease

J. Biol. Chem., 270 (1995), pp. 17610-17615



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Castellano et al., 2011](#) J.M. Castellano, J. Kim, F.R. Stewart, H. Jiang, R.B. DeMattos, B.W. Patterson, A.M. Fagan, J.C. Morris, K.G. Mawuenyega, C. Cruchaga, *et al.*

Human apoE isoforms differentially regulate brain amyloid- $\beta$  peptide clearance. $\beta$

Sci. Transl. Med., 3 (2011), p. 89ra57

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Castellano et al., 2012](#) J.M. Castellano, R. Deane, A.J. Gottesdiener, P.B. Verghese, F.R. Stewart, T. West, A.C. Paoletti, T.R. Kasper, R.B. DeMattos, B.V. Zlokovic, D.M. Holtzman

Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood A $\beta$  clearance in a mouse model of  $\beta$ -amyloidosis. $\beta\beta$

Proc. Natl. Acad. Sci. USA, 109 (2012), pp. 15502-15507

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Chen et al., 2011](#) J. Chen, Q. Li, J. Wang

Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions

Proc. Natl. Acad. Sci. USA, 108 (2011), pp. 14813-14818

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Corder et al., 1993](#) E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines, M.A. Pericak-Vance

## Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Science, 261 (1993), pp. 921-923

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Davignon et al., 1988](#) J. Davignon, D. Bouthillier, A.C. Nestruck, C.F. Sing

## Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians

Trans. Am. Clin. Climatol. Assoc., 99 (1988), pp. 100-110

[Google Scholar ↗](#)

[Davis et al., 2020](#) A.A. Davis, C.E. Inman, Z.M. Wargel, U. Dube, B.M. Freeberg, A. Galluppi, J.N. Haines, D.D. Dhavale, R. Miller, F.A. Choudhury, *et al.*

## APOE genotype regulates pathology and disease progression in synucleinopathy

Sci. Transl. Med., 12 (2020), pp. 1-15

[View in Scopus ↗](#) [Google Scholar ↗](#)

[DeMattos et al., 1998](#) R.B. DeMattos, L.K. Curtiss, D.L. Williams

## A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins

J. Biol. Chem., 273 (1998), pp. 4206-4212

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[DeMattos et al., 2001](#) R.B. DeMattos, L.L. Rudel, D.L. Williams

## Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth

J. Lipid Res., 42 (2001), pp. 976-987

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Dickson et al., 2018](#) D.W. Dickson, M.G. Heckman, M.E. Murray, A.I. Soto, R.L. Walton, N.N. Diehl, J.A. van Gerpen, R.J. Uitti, Z.K. Wszolek, N. Ertekin-Taner, *et al.*

## APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology.ε

Neurology, 91 (2018), pp. e1182-e1195

[Google Scholar ↗](#)

[Dong and Weisgraber, 1996](#) L.-M. Dong, K.H. Weisgraber

Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins  
J. Biol. Chem., 271 (1996), pp. 19053-19057

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Dong et al., 1994](#) L.M. Dong, C. Wilson, M.R. Wardell, T. Simmons, R.W. Mahley, K.H. Weisgraber, D.A. Agard

Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms

J. Biol. Chem., 269 (1994), pp. 22358-22365

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Dong et al., 2001](#) J. Dong, C.A. Peters-Libeu, K.H. Weisgraber, B.W. Segelke, B. Rupp, I. Capila, M.J. Hernáiz, L.A. LeBrun, R.J. Linhardt

Interaction of the N-terminal domain of apolipoprotein E4 with heparin

Biochemistry, 40 (2001), pp. 2826-2834

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Eto et al., 1987](#) M. Eto, K. Watanabe, Y. Iwashima, A. Morikawa, N. Chonan, E. Oshima, M. Sekiguchi, K. Ishii

Increased frequency of apolipoprotein epsilon 4 allele in type II diabetes with hypercholesterolemia

Diabetes, 36 (1987), pp. 1301-1306

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Eto et al., 1991](#) M. Eto, K. Watanabe, I. Makino

Relationship of metabolic control and body weight to hypercholesterolemia in NIDDM patients with apolipoprotein E4

Diabetes Care, 14 (1991), pp. 127-129

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Fagan et al., 1999](#) A.M. Fagan, D.M. Holtzman, G. Munson, T. Mathur, D. Schneider, L.K. Chang, G.S. Getz, C.A. Reardon, J. Lukens, J.A. Shah, M.J. LaDu

Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice

J. Biol. Chem., 274 (1999), pp. 30001-30007

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Fagan et al., 2002](#) A.M. Fagan, M. Watson, M. Parsadanian, K.R. Bales, S.M. Paul, D.M. Holtzman

## Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease

Neurobiol. Dis., 9 (2002), pp. 305-318



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Fisher et al., 2000](#) C.A. Fisher, V. Narayanaswami, R.O. Ryan

## The lipid-associated conformation of the low density lipoprotein receptor binding domain of human apolipoprotein E

J. Biol. Chem., 275 (2000), pp. 33601-33606



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Fitz et al., 2010](#) N.F. Fitz, A. Cronican, T. Pham, A. Fogg, A.H. Fauq, R. Chapman, I. Lefterov, R. Koldamova

## Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice

J. Neurosci., 30 (2010), pp. 6862-6872

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Frieden et al., 2017](#) C. Frieden, H. Wang, C.M.W. Ho

## A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions

Proc. Natl. Acad. Sci. USA, 114 (2017), pp. 6292-6297

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Fryer et al., 2005](#) J.D. Fryer, R.B. Demattos, L.M. McCormick, M.A. O'Dell, M.L. Spinner, K.R. Bales, S.M. Paul, P.M. Sullivan, M. Parsadanian, G. Bu, D.M. Holtzman

## The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice

J. Biol. Chem., 280 (2005), pp. 25754-25759



[View PDF](#) [View article](#) [Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Futamura et al., 2005](#) M. Futamura, P. Dhanasekaran, T. Handa, M.C. Phillips, S. Lund-Katz, H. Saito

## Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces

J. Biol. Chem., 280 (2005), pp. 5414-5422



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Garai et al., 2011](#) K. Garai, B. Baban, C. Frieden

## Dissociation of apolipoprotein E oligomers to monomer is required for high-affinity binding to phospholipid vesicles

Biochemistry, 50 (2011), pp. 2550-2558

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Garai et al., 2014](#) K. Garai, P.B. Verghese, B. Baban, D.M. Holtzman, C. Frieden

## The binding of apolipoprotein E to oligomers and fibrils of amyloid- $\beta$ alters the kinetics of amyloid aggregation

Biochemistry, 53 (2014), pp. 6323-6331

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Ghosh et al., 2019](#) S. Ghosh, T.B. Sil, S. Dolai, K. Garai

## High-affinity multivalent interactions between apolipoprotein E and the oligomers of amyloid- $\beta$

FEBS J., 286 (2019), pp. 4737-4753

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Goldstein and Brown, 1976](#) J.L. Goldstein, M.S. Brown

## The LDL pathway in human fibroblasts: a receptor-mediated mechanism for the regulation of cholesterol metabolism

Curr. Top. Cell. Regul., 11 (1976), pp. 147-181

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Grimm et al., 2017](#) M.O.W. Grimm, D.M. Michaelson, T. Hartmann

## Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention

J. Lipid Res., 58 (2017), pp. 2083-2101

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Gunzburg et al., 2007](#) M.J. Gunzburg, M.A. Perugini, G.J. Howlett

## Structural basis for the recognition and cross-linking of amyloid fibrils by human apolipoprotein E

J. Biol. Chem., 282 (2007), pp. 35831-35841

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Guttman et al., 2010](#) M. Guttman, J.H. Prieto, T.M. Handel, P.J. Domaille, E.A. Komives


## Structure of the minimal interface between ApoE and LRP


J. Mol. Biol., 398 (2010), pp. 306-319

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Hashimoto et al., 2012](#) T. Hashimoto, A. Serrano-Pozo, Y. Hori, K.W. Adams, S. Takeda, A.O. Banerji, A. Mitani, D. Joyner, D.H. Thyssen, B.J. Bacskai, *et al.*  
**Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid  $\beta$  peptide.**  
J. Neurosci., 32 (2012), pp. 15181-15192  
[View in Scopus ↗](#) [Google Scholar ↗](#)

[Hatters et al., 2005](#) D.M. Hatters, C.A. Peters-Libeu, K.H. Weisgraber  
**Engineering conformational destabilization into mouse apolipoprotein E. A model for a unique property of human apolipoprotein E4**  
J. Biol. Chem., 280 (2005), pp. 26477-26482  
 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Hatters et al., 2006](#) D.M. Hatters, C.A. Peters-Libeu, K.H. Weisgraber  
**Apolipoprotein E structure: insights into function**  
Trends Biochem. Sci., 31 (2006), pp. 445-454  
 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Hatters et al., 2009](#) D.M. Hatters, J.C. Voss, M.S. Budamagunta, Y.N. Newhouse, K.H. Weisgraber  
**Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy**  
J. Mol. Biol., 386 (2009), pp. 261-271  
 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Heinsinger et al., 2016](#) N.M. Heinsinger, M.A. Gachechiladze, G.W. Rebeck  
**Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid**  
J. Neuropathol. Exp. Neurol., 75 (2016), pp. 918-924  
[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Henry et al., 2018](#) N. Henry, E.-M. Krammer, F. Stengel, Q. Adams, F. Van Liefferinge, E. Hubin, R. Chaves, R. Efremov, R. Aebbersold, G. Vandebussche, *et al.*  
**Lipidated apolipoprotein E4 structure and its receptor binding mechanism determined by a combined cross-linking coupled to mass spectrometry and molecular dynamics approach**  
PLoS Comput. Biol., 14 (2018), p. e1006165  
[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Hirsch-Reinshagen et al., 2004](#) V. Hirsch-Reinshagen, S. Zhou, B.L. Burgess, L. Bernier, S.A. McIsaac, J.Y. Chan, G.H. Tansley, J.S. Cohn, M.R. Hayden, C.L. Wellington  
**Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain**  
J. Biol. Chem., 279 (2004), pp. 41197-41207



[View PDF](#)

[View article](#)

[View in Scopus ↗](#)

[Google Scholar ↗](#)

[Hirsch-Reinshagen et al., 2005](#) V. Hirsch-Reinshagen, L.F. Maia, B.L. Burgess, J.F. Blain, K.E. Naus, S.A. McIsaac, P.F. Parkinson, J.Y. Chan, G.H. Tansley, M.R. Hayden, *et al.*  
**The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease**  
J. Biol. Chem., 280 (2005), pp. 43243-43256



[View PDF](#)

[View article](#)

[View in Scopus ↗](#)

[Google Scholar ↗](#)

[Holtzman et al., 1999](#) D.M. Holtzman, K.R. Bales, S. Wu, P. Bhat, M. Parsadanian, A.M. Fagan, L.K. Chang, Y. Sun, S.M. Paul  
**Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease**  
J. Clin. Invest., 103 (1999), pp. R15-R21

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Holtzman et al., 2000](#) D.M. Holtzman, K.R. Bales, T. Tenkova, A.M. Fagan, M. Parsadanian, L.J. Sartorius, B. Mackey, J. Olney, D. McKeel, D. Wozniak, S.M. Paul  
**Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease**  
Proc. Natl. Acad. Sci. USA, 97 (2000), pp. 2892-2897

[View in Scopus ↗](#) [Google Scholar ↗](#)


[Holtzman et al., 2012](#) D.M. Holtzman, J. Herz, G. Bu  
**Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease**  
Cold Spring Harb. Perspect. Med., 2 (2012), p. a006312


[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Hu et al., 2015](#) J. Hu, C.-C. Liu, X.-F. Chen, Y.-W. Zhang, H. Xu, G. Bu  
**Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A $\beta$  metabolism in apoE4-targeted replacement mice. $\beta$**   
Mol. Neurodegener., 10 (2015), p. 6

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Huang et al., 2017](#) Y.A. Huang, B. Zhou, M. Wernig, T.C. Südhof  
ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and A $\beta$  Secretion. $\beta$   
Cell, 168 (2017), pp. 427-441  
[Google Scholar ↗](#)

[Huebbe and Rimbach, 2017](#) P. Huebbe, G. Rimbach  
Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors  
Ageing Res. Rev., 37 (2017), pp. 146-161  
 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Hui et al., 1984](#) D.Y. Hui, T.L. Innerarity, R.W. Mahley  
Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E. $\beta$   
J. Biol. Chem., 259 (1984), pp. 860-869  
 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Huynh et al., 2017](#) T.V. Huynh, F. Liao, C.M. Francis, G.O. Robinson, J.R. Serrano, H. Jiang, J. Roh, M.B. Finn, P.M. Sullivan, T.J. Esparza, *et al.*  
Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of  $\beta$ -amyloidosis  
Neuron, 96 (2017), pp. 1013-1023  
[View in Scopus ↗](#) [Google Scholar ↗](#)

[Huynh et al., 2019](#) T.V. Huynh, C. Wang, A.C. Tran, G.T. Tabor, T.E. Mahan, C.M. Francis, M.B. Finn, R. Spellman, M. Manis, R.E. Tanzi, *et al.*  
Lack of hepatic apoE does not influence early A $\beta$  deposition: observations from a new APOE knock-in model. $\beta$   
Mol. Neurodegener., 14 (2019), p. 37  
[Google Scholar ↗](#)

[Innerarity and Mahley, 1978](#) T.L. Innerarity, R.W. Mahley  
Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins  
Biochemistry, 17 (1978), pp. 1440-1447  
[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)



[Innerarity et al., 1979](#) T.L. Innerarity, R.E. Pitas, R.W. Mahley

**Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts**

J. Biol. Chem., 254 (1979), pp. 4186-4190



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Innerarity et al., 1983](#) T.L. Innerarity, E.J. Friedlander, S.C. Rall Jr., K.H. Weisgraber, R.W. Mahley

**The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments**

J. Biol. Chem., 258 (1983), pp. 12341-12347



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Innerarity et al., 1984](#) T.L. Innerarity, K.H. Weisgraber, K.S. Arnold, S.C.J. Rall Jr., R.W. Mahley

**Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation**

J. Biol. Chem., 259 (1984), pp. 7261-7267



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Jackson et al., 1975](#) R.L. Jackson, J.D. Morrisett, A.M. Gotto Jr., J.P. Segrest

**The mechanism of lipid-binding by plasma lipoproteins**

Mol. Cell. Biochem., 6 (1975), pp. 43-50

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Ji et al., 2002](#) Z.-S. Ji, R.D. Miranda, Y.M. Newhouse, K.H. Weisgraber, Y. Huang, R.W. Mahley

**Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells**

J. Biol. Chem., 277 (2002), pp. 21821-21828



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Ji et al., 2006](#) Z.-S. Ji, K. Müllendorff, I.H. Cheng, R.D. Miranda, Y. Huang, R.W. Mahley

**Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration**

J. Biol. Chem., 281 (2006), pp. 2683-2692



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Jones et al., 2011](#) P.B. Jones, K.W. Adams, A. Rozkalne, T.L. Spires-Jones, T.T. Hshieh, T. Hashimoto, C.A.

von Armin, M. Mielke, B.J. Bacskai, B.T. Hyman

**Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid- $\beta$  in human Alzheimer brain**

PLoS ONE, 6 (2011), p. e14586

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Kanekiyo et al., 2013](#) T. Kanekiyo, J.R. Cirrito, C.-C. Liu, M. Shinohara, J. Li, D.R. Schuler, M. Shinohara, D.M. Holtzman, G. Bu

### Neuronal clearance of amyloid- $\beta$ by endocytic receptor LRP1

J. Neurosci., 33 (2013), pp. 19276-19283

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Kim et al., 2009](#) J. Kim, J.M. Castellano, H. Jiang, J.M. Basak, M. Parsadanian, V. Pham, S.M. Mason, S.M. Paul, D.M. Holtzman

### Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance

Neuron, 64 (2009), pp. 632-644

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Kim et al., 2011](#) J. Kim, H. Jiang, S. Park, A.E.M. Eltorai, F.R. Stewart, H. Yoon, J.M. Basak, M.B. Finn, D.M. Holtzman

### Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid- $\beta$ amyloidosis. $\beta$

J. Neurosci., 31 (2011), pp. 18007-18012

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Koldamova et al., 2005](#) R. Koldamova, M. Staufenbiel, I. Lefterov

### Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice

J. Biol. Chem., 280 (2005), pp. 43224-43235

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Krasemann et al., 2017](#) S. Krasemann, C. Madore, R. Cialic, C. Baufeld, N. Calcagno, R. El Fatimy, L. Beckers, E. O'Loughlin, Y. Xu, Z. Fanek, *et al.*

### The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases

Immunity, 47 (2017), pp. 566-581

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Krimbou et al., 2004](#) L. Krimbou, M. Denis, B. Haidar, M. Carrier, M. Marcil, J. Genest Jr.

### Molecular interactions between apoE and ABCA1: impact on apoE lipidation

J. Lipid Res., 45 (2004), pp. 839-848

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Kuszczyk et al., 2013](#) M.A. Kuszczyk, S. Sanchez, J. Pankiewicz, J. Kim, M. Duszczak, M. Guridi, A.A. Asuni, P.M. Sullivan, D.M. Holtzman, M.J. Sadowski  
**Blocking the interaction between apolipoprotein E and A $\beta$  reduces intraneuronal accumulation of A $\beta$  and inhibits synaptic degeneration**  
Am. J. Pathol., 182 (2013), pp. 1750-1768



[View PDF](#)

[View article](#)

[View in Scopus](#)

[Google Scholar](#)

[LaDu et al., 1994](#) M.J. LaDu, M.T. Falduto, A.M. Manelli, C.A. Reardon, G.S. Getz, D.E. Frail  
**Isoform-specific binding of apolipoprotein E to  $\beta$ -amyloid**  
J. Biol. Chem., 269 (1994), pp. 23403-23406



[View PDF](#)

[View article](#)

[View in Scopus](#)

[Google Scholar](#)

[LaDu et al., 1995](#) M.J. LaDu, T.M. Pederson, D.E. Frail, C.A. Reardon, G.S. Getz, M.T. Falduto  
**Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid**  
J. Biol. Chem., 270 (1995), pp. 9039-9042



[View PDF](#)

[View article](#)

[View in Scopus](#)

[Google Scholar](#)

[Lalazar et al., 1988](#) A. Lalazar, K.H. Weisgraber, S.C. Rall Jr., H. Giladi, T.L. Innerarity, A.Z. Levanon, J.K. Boyles, B. Amit, M. Gorecki, R.W. Mahley, *et al.*  
**Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions**  
J. Biol. Chem., 263 (1988), pp. 3542-3545



[View PDF](#)

[View article](#)

[View in Scopus](#)

[Google Scholar](#)

[Landschulz et al., 1996](#) K.T. Landschulz, R.K. Pathak, A. Rigotti, M. Krieger, H.H. Hobbs  
**Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat**  
J. Clin. Invest., 98 (1996), pp. 984-995

[View in Scopus](#) [Google Scholar](#)

[Li et al., 1988](#) W.H. Li, M. Tanimura, C.C. Luo, S. Datta, L. Chan  
**The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution**  
J. Lipid Res., 29 (1988), pp. 245-271



[View PDF](#)

[View article](#)

[View in Scopus](#)

[Google Scholar](#)

[Liao et al., 2018](#) F. Liao, A. Li, M. Xiong, N. Bien-Ly, H. Jiang, Y. Zhang, M.B. Finn, R. Hoyle, J. Keyser, K.B. Lefton, *et al.*

## Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation

J. Clin. Invest., 128 (2018), pp. 2144-2155

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Liu et al., 2013](#) C.-C. Liu, C.-C. Liu, T. Kanekiyo, H. Xu, G. Bu

## Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

Nat. Rev. Neurol., 9 (2013), pp. 106-118

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Liu et al., 2017](#) C.-C. Liu, J. Hu, N. Zhao, J. Wang, N. Wang, J.R. Cirrito, T. Kanekiyo, D.M. Holtzman, G. Bu

## Astrocytic LRP1 Mediates Brain A $\beta$ Clearance and Impacts Amyloid Deposition. $\beta$

J. Neurosci., 37 (2017), pp. 4023-4031

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Ly et al., 2013](#) S. Ly, R. Altman, J. Petrova, Y. Lin, S. Hilt, T. Huser, T.A. Laurence, J.C. Voss  
Binding of apolipoprotein E inhibits the oligomer growth of amyloid- $\beta$  peptide in solution as determined by fluorescence cross-correlation spectroscopy. $\beta$

J. Biol. Chem., 288 (2013), pp. 11628-11635



[View PDF](#) [View article](#) [Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Ma et al., 1994](#) J. Ma, A. Yee, H.B.J. Brewer Jr., S. Das, H. Potter

## Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments

Nature, 372 (1994), pp. 92-94

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Mahley, 1988](#) R.W. Mahley

## Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

Science, 240 (1988), pp. 622-630

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Mahley and Huang, 2012](#) R.W. Mahley, Y. Huang

## Apolipoprotein e sets the stage: response to injury triggers neuropathology

Neuron, 76 (2012), pp. 871-885



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Mahley et al., 1979](#) R.W. Mahley, K.H. Weisgraber, T.L. Innerarity  
Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors  
Biochim. Biophys. Acta, 575 (1979), pp. 81-91

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Mahley et al., 2009](#) R.W. Mahley, K.H. Weisgraber, Y. Huang  
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS  
J. Lipid Res., 50 (Suppl) (2009), pp. S183-S188

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Mann et al., 1989](#) W.A. Mann, R.E. Gregg, D.L. Sprecher, H.B. Brewer Jr.  
Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia  
Biochim. Biophys. Acta, 1005 (1989), pp. 239-244

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Morris et al., 2010](#) J.C. Morris, C.M. Roe, C. Xiong, A.M. Fagan, A.M. Goate, D.M. Holtzman, M.A. Mintun  
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging  
Ann. Neurol., 67 (2010), pp. 122-131

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Morrow et al., 2000](#) J.A. Morrow, K.S. Arnold, J. Dong, M.E. Balestra, T.L. Innerarity, K.H. Weisgraber  
Effect of arginine 172 on the binding of apolipoprotein E to the low density lipoprotein receptor  
J. Biol. Chem., 275 (2000), pp. 2576-2580

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Morrow et al., 2002](#) J.A. Morrow, D.M. Hatters, B. Lu, P. Hochtl, K.A. Oberg, B. Rupp, K.H. Weisgraber  
Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease  
J. Biol. Chem., 277 (2002), pp. 50380-50385

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Näslund et al., 1995](#) J. Näslund, J. Thyberg, L.O. Tjernberg, C. Wernstedt, A.R. Karlström, N. Bogdanovic, S.E. Gandy, L. Lannfelt, L. Terenius, C. Nordstedt

## Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain

Neuron, 15 (1995), pp. 219-228



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Newman et al., 1985](#) T.C. Newman, P.A. Dawson, L.L. Rudel, D.L. Williams

## Quantitation of apolipoprotein E mRNA in the liver and peripheral tissues of nonhuman primates

J. Biol. Chem., 260 (1985), pp. 2452-2457



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Parhizkar et al., 2019](#) S. Parhizkar, T. Arzberger, M. Brendel, G. Kleinberger, M. Deussing, C. Focke, B. Nuscher, M. Xiong, A. Ghasemigharagoz, N. Katzmarski, *et al.*

## Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE

Nat. Neurosci., 22 (2019), pp. 191-204

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Peters-Libeu et al., 2006](#) C.A. Peters-Libeu, Y. Newhouse, D.M. Hatters, K.H. Weisgraber

## Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine

J. Biol. Chem., 281 (2006), pp. 1073-1079



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Pitas et al., 1987](#) R.E. Pitas, J.K. Boyles, S.H. Lee, D. Foss, R.W. Mahley

## Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins

Biochim. Biophys. Acta, 917 (1987), pp. 148-161



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Rall et al., 1983](#) S.C. Rall Jr., K.H. Weisgraber, T.L. Innerarity, R.W. Mahley

## Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia

J. Clin. Invest., 71 (1983), pp. 1023-1031

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Raulin et al., 2019](#) A.C. Raulin, L. Kraft, Y.K. Al-Hilaly, W.F. Xue, J.E. McGeehan, J.R. Atack, L. Serpell

## The Molecular Basis for Apolipoprotein E4 as the Major Risk Factor for Late-Onset Alzheimer's Disease

J. Mol. Biol., 431 (2019), pp. 2248-2265

 [View PDF](#)   [View article](#)   [View in Scopus ↗](#)   [Google Scholar ↗](#)

[Raussens et al., 1998](#) V. Raussens, C.A. Fisher, E. Goormaghtigh, R.O. Ryan, J.M. Ruyschaert  
**The low density lipoprotein receptor active conformation of apolipoprotein E. Helix organization in n-terminal domain-phospholipid disc particles**  
J. Biol. Chem., 273 (1998), pp. 25825-25830

 [View PDF](#)   [View article](#)   [View in Scopus ↗](#)   [Google Scholar ↗](#)

[Ray et al., 2017](#) A. Ray, N. Ahalawat, J. Mondal  
**Atomistic Insights into Structural Differences between E3 and E4 Isoforms of Apolipoprotein E**  
Biophys. J., 113 (2017), pp. 2682-2694

 [View PDF](#)   [View article](#)   [View in Scopus ↗](#)   [Google Scholar ↗](#)

[Reiman et al., 2009](#) E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, W. Lee, N. Ayutyanont, J. Keppler, S.A. Reeder, J.B.S. Langbaum, *et al.*  
**Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease**  
Proc. Natl. Acad. Sci. USA, 106 (2009), pp. 6820-6825

[Crossref ↗](#)   [View in Scopus ↗](#)   [Google Scholar ↗](#)

[Saito et al., 2003](#) H. Saito, P. Dhanasekaran, D. Nguyen, P. Holvoet, S. Lund-Katz, M.C. Phillips  
**Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model**  
J. Biol. Chem., 278 (2003), pp. 23227-23232

 [View PDF](#)   [View article](#)   [View in Scopus ↗](#)   [Google Scholar ↗](#)

[Saito et al., 2004](#) M. Saito, M. Eto, H. Nitta, Y. Kanda, M. Shigeto, K. Nakayama, K. Tawaramoto, F. Kawasaki, S. Kamei, K. Kohara, *et al.*  
**"Effect of apoE4 allele on plasma LDLcholesterol response to diet therapy in type 2 diabetic patients". Apunts**  
Medicina de L'Esport, 39 (2004), pp. 41-42

 [View PDF](#)   [View article](#)   [Crossref ↗](#)   [View in Scopus ↗](#)   [Google Scholar ↗](#)

[Sanan et al., 1994](#) D.A. Sanan, K.H. Weisgraber, S.J. Russell, R.W. Mahley, D. Huang, A. Saunders, D. Schmechel, T. Wisniewski, B. Frangione, A.D. Roses, *et al.*  
**Apolipoprotein E associates with  $\beta$  amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3**  
J. Clin. Invest., 94 (1994), pp. 860-869

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Segrest et al., 1992](#) J.P. Segrest, M.K. Jones, H. De Loof, C.G. Brouillette, Y.V. Venkatachalapathi, G.M. Anantharamaiah

### The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function

J. Lipid Res., 33 (1992), pp. 141-166

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Shaw et al., 1997](#) R.A. Shaw, G.W. Buchko, G. Wang, A. Rozek, W.D. Treleaven, H.H. Mantsch, R.J. Cushley

### Infrared spectroscopy of human apolipoprotein fragments in SDS/D2O: relative lipid-binding affinities and a novel amide I assignment

Biochemistry, 36 (1997), pp. 14531-14538

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Shi et al., 2017](#) Y. Shi, K. Yamada, S.A. Liddelow, S.T. Smith, L. Zhao, W. Luo, R.M. Tsai, S. Spina, L.T. Grinberg, J.C. Rojas, *et al.*, Alzheimer's Disease Neuroimaging Initiative

### ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

Nature, 549 (2017), pp. 523-527

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Shi et al., 2019](#) Y. Shi, M. Manis, J. Long, K. Wang, P.M. Sullivan, J. Remolina Serrano, R. Hoyle, D.M. Holtzman

### Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model

J. Exp. Med., 216 (2019), pp. 2546-2561

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Shore and Shore, 1973](#) V.G. Shore, B. Shore

### Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components

Biochemistry, 12 (1973), pp. 502-507

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Sparrow et al., 1992](#) J.T. Sparrow, D.A. Sparrow, G. Fernando, A.R. Culwell, M. Kovar, A.M. Gotto Jr.

### Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus

Biochemistry, 31 (1992), pp. 1065-1068



[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Strittmatter et al., 1993a](#) W.J. Strittmatter, A.M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G.S. Salvesen, A.D. Roses

### Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

Proc. Natl. Acad. Sci. USA, 90 (1993), pp. 1977-1981

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Strittmatter et al., 1993b](#) W.J. Strittmatter, K.H. Weisgraber, D.Y. Huang, L.M. Dong, G.S. Salvesen, M. Pericak-Vance, D. Schmechel, A.M. Saunders, D. Goldgaber, A.D. Roses

### Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease

Proc. Natl. Acad. Sci. USA, 90 (1993), pp. 8098-8102

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Tachibana et al., 2019](#) M. Tachibana, M.-L. Holm, C.-C. Liu, M. Shinohara, T. Aikawa, H. Oue, Y. Yamazaki, Y.A. Martens, M.E. Murray, P.M. Sullivan, *et al.*

### APOE4-mediated amyloid- $\beta$ pathology depends on its neuronal receptor LRP1

J. Clin. Invest., 129 (2019), pp. 1272-1277

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Tai et al., 2013](#) L.M. Tai, T. Bilousova, L. Jungbauer, S.K. Roeske, K.L. Youmans, C. Yu, W.W. Poon, L.B. Cornwell, C.A. Miller, H.V. Vinters, *et al.*

### Levels of soluble apolipoprotein E/amyloid- $\beta$ (A $\beta$ ) complex are reduced and oligomeric A $\beta$ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples

J. Biol. Chem., 288 (2013), pp. 5914-5926

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Tsuang et al., 2013](#) D. Tsuang, J.B. Leverenz, O.L. Lopez, R.L. Hamilton, D.A. Bennett, J.A. Schneider, A.S. Buchman, E.B. Larson, P.K. Crane, J.A. Kaye, *et al.*

### APOE $\epsilon$ 4 increases risk for dementia in pure synucleinopathies. $\epsilon$

JAMA Neurol., 70 (2013), pp. 223-228

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Ulrich et al., 2018](#) J.D. Ulrich, T.K. Ulland, T.E. Mahan, S. Nyström, K.P. Nilsson, W.M. Song, Y. Zhou, M. Reinartz, S. Choi, H. Jiang, *et al.*

### ApoE facilitates the microglial response to amyloid plaque pathology

J. Exp. Med., 215 (2018), pp. 1047-1058

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Utermann, 1975](#) G. Utermann

Isolation and partial characterization of an arginine-rich apolipoprotein from human plasma very-low-density lipoproteins: apolipoprotein E

Hoppe Seylers Z. Physiol. Chem., 356 (1975), pp. 1113-1121

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Verghese et al., 2013](#) P.B. Verghese, J.M. Castellano, K. Garai, Y. Wang, H. Jiang, A. Shah, G. Bu, C. Frieden, D.M. Holtzman

ApoE influences amyloid- $\beta$  (A $\beta$ ) clearance despite minimal apoE/A $\beta$  association in physiological conditions

Proc. Natl. Acad. Sci. USA, 110 (2013), pp. E1807-E1816

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Wahrle et al., 2004](#) S.E. Wahrle, H. Jiang, M. Parsadanian, J. Legleiter, X. Han, J.D. Fryer, T. Kowalewski, D.M. Holtzman

ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE

J. Biol. Chem., 279 (2004), pp. 40987-40993



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Wahrle et al., 2005](#) S.E. Wahrle, H. Jiang, M. Parsadanian, R.E. Hartman, K.R. Bales, S.M. Paul, D.M. Holtzman

Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease

J. Biol. Chem., 280 (2005), pp. 43236-43242



[View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Wahrle et al., 2008](#) S.E. Wahrle, H. Jiang, M. Parsadanian, J. Kim, A. Li, A. Knoten, S. Jain, V. Hirsch-Reinshagen, C.L. Wellington, K.R. Bales, *et al.*

Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease

J. Clin. Invest., 118 (2008), pp. 671-682

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Wang et al., 1996a](#) G. Wang, G.K. Pierens, W.D. Treleaven, J.T. Sparrow, R.J. Cushley

Conformations of human apolipoprotein E(263-286) and E(267-289) in aqueous solutions of sodium dodecyl sulfate by CD and <sup>1</sup>H NMR

Biochemistry, 35 (1996), pp. 10358-10366

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Wang et al., 2018](#) C. Wang, R. Najm, Q. Xu, D.E. Jeong, D. Walker, M.E. Balestra, S.Y. Yoon, H. Yuan, G. Li, Z.A. Miller, *et al.*

### Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector

Nat. Med., 24 (2018), pp. 647-657

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Wang et al., 1996b](#) G. Wang, W.D. Treleaven, R.J. Cushley

### Conformation of human serum apolipoprotein A-I(166-185) in the presence of sodium dodecyl sulfate or dodecylphosphocholine by <sup>1</sup>H-NMR and CD. Evidence for specific peptide-SDS interactions

Biochim. Biophys. Acta, 1301 (1996), pp. 174-184

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Wardell et al., 1982](#) M.R. Wardell, P.A. Suckling, E.D. Janus

### Genetic variation in human apolipoprotein E

J. Lipid Res., 23 (1982), pp. 1174-1182

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Weisgraber, 1990](#) K.H. Weisgraber

### Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112

J. Lipid Res., 31 (1990), pp. 1503-1511

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Weisgraber, 1994](#) K.H. Weisgraber

### Apolipoprotein E: Structure-Function Relationships

C.B. Anfinsen, J.T. Edsall, F.M. Richards, D.S. Eisenberg eds. (Eds.), *Advances in Protein Chemistry*, Elsevier (1994), pp. 249-302

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Weisgraber et al., 1982](#) K.H. Weisgraber, T.L. Innerarity, R.W. Mahley

### Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site

J. Biol. Chem., 257 (1982), pp. 2518-2521

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Weisgraber et al., 1983](#) K.H. Weisgraber, S.C.J. Rall Jr., T.P. Bersot, R.W. Mahley, G. Franceschini, C.R. Sirtori  
**Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I**  
J. Biol. Chem., 258 (1983), pp. 2508-2513

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Wernette-Hammond et al., 1989](#) M.E. Wernette-Hammond, S.J. Lauer, A. Corsini, D. Walker, J.M. Taylor, S.C. Rall Jr.  
**Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194**  
J. Biol. Chem., 264 (1989), pp. 9094-9101

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Williams et al., 1985](#) D.L. Williams, P.A. Dawson, T.C. Newman, L.L. Rudel  
**Apolipoprotein E synthesis in peripheral tissues of nonhuman primates**  
J. Biol. Chem., 260 (1985), pp. 2444-2451

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Williams et al., 2015](#) B. Williams 2nd, M. Convertino, J. Das, N.V. Dokholyan  
**ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations**  
PLoS Comput. Biol., 11 (2015), p. e1004359

[Google Scholar ↗](#)

[Wilson et al., 1991](#) C. Wilson, M.R. Wardell, K.H. Weisgraber, R.W. Mahley, D.A. Agard  
**Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E**  
Science, 252 (1991), pp. 1817-1822

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Wilson et al., 1994](#) C. Wilson, T. Mau, K.H. Weisgraber, M.R. Wardell, R.W. Mahley, D.A. Agard  
**Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein**  
Structure, 2 (1994), pp. 713-718

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Winkler et al., 1999](#) K. Winkler, H. Scharnagl, U. Tisljar, H. Hoschützky, I. Friedrich, M.M. Hoffmann, M. Hüttinger, H. Wieland, W. März

## Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis

J. Lipid Res., 40 (1999), pp. 447-455



[View PDF](#)

[View article](#)

[View in Scopus ↗](#)

[Google Scholar ↗](#)

[Wisniewski and Frangione, 1992](#) T. Wisniewski, B. Frangione

## Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

Neurosci. Lett., 135 (1992), pp. 235-238



[View PDF](#)

[View article](#)

[View in Scopus ↗](#)

[Google Scholar ↗](#)

[Wisniewski et al., 1993](#) T. Wisniewski, A. Golabek, E. Matsubara, J. Ghiso, B. Frangione

## Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid

Biochem. Biophys. Res. Commun., 192 (1993), pp. 359-365



[View PDF](#)

[View article](#)

[View in Scopus ↗](#)

[Google Scholar ↗](#)

[Xu et al., 2004](#) Q. Xu, W.J. Brecht, K.H. Weisgraber, R.W. Mahley, Y. Huang

## Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer

J. Biol. Chem., 279 (2004), pp. 25511-25516



[View PDF](#)

[View article](#)

[View in Scopus ↗](#)

[Google Scholar ↗](#)

[Yamamoto et al., 2007](#) M. Yamamoto, T. Kiyota, M. Horiba, J.L. Buescher, S.M. Walsh, H.E.

Gendelman, T. Ikezu

## Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice

Am. J. Pathol., 170 (2007), pp. 680-692



[View PDF](#)

[View article](#)

[Crossref ↗](#)

[View in Scopus ↗](#)

[Google Scholar ↗](#)

[Yamamoto et al., 2008](#) T. Yamamoto, H.W. Choi, R.O. Ryan

## Apolipoprotein E isoform-specific binding to the low-density lipoprotein receptor

Anal. Biochem., 372 (2008), pp. 222-226



[View PDF](#)

[View article](#)

[View in Scopus ↗](#)

[Google Scholar ↗](#)

[Yamauchi et al., 2008](#) Y. Yamauchi, N. Deguchi, C. Takagi, M. Tanaka, P. Dhanasekaran, M. Nakano,

T. Handa, M.C. Phillips, S. Lund-Katz, H. Saito

## Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon

## resonance study

Biochemistry, 47 (2008), pp. 6702-6710

[Crossref ↗](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Youmans et al., 2012](#) K.L. Youmans, L.M. Tai, E. Nwabuisi-Heath, L. Jungbauer, T. Kanekiyo, M. Gan, J. Kim, W.A. Eimer, S. Estus, G.W. Rebeck, *et al.*

## APOE4-specific changes in A $\beta$ accumulation in a new transgenic mouse model of Alzheimer disease

J. Biol. Chem., 287 (2012), pp. 41774-41786

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Zhang et al., 2010](#) L. Zhang, J. Song, Y. Newhouse, S. Zhang, K.H. Weisgraber, G. Ren

## An optimized negative-staining protocol of electron microscopy for apoE4 POPC lipoprotein

J. Lipid Res., 51 (2010), pp. 1228-1236

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Zhang et al., 2013](#) L. Zhang, H. Tong, M. Garewal, G. Ren

## Optimized negative-staining electron microscopy for lipoprotein studies

Biochim. Biophys. Acta, 1830 (2013), pp. 2150-2159

 [View PDF](#) [View article](#) [View in Scopus ↗](#) [Google Scholar ↗](#)

[Zhao et al., 2018](#) N. Zhao, C.-C. Liu, A.J. Van Ingelgom, C. Linares, A. Kurti, J.A. Knight, M.G.

Heckman, N.N. Diehl, M. Shinohara, Y.A. Martens, *et al.*

## APOE $\epsilon$ 2 is associated with increased tau pathology in primary tauopathy

Nat. Commun., 9 (2018), p. 4388

[View in Scopus ↗](#) [Google Scholar ↗](#)

[Zhao et al., 2020](#) N. Zhao, O.N. Attrebi, Y. Ren, W. Qiao, B. Sonustun, Y.A. Martens, A.D. Meneses, F. Li, F. Shue, J. Zheng, *et al.*

## APOE4 exacerbates $\alpha$ -synuclein pathology and related toxicity independent of amyloid

Sci. Trans. Med., 12 (2020), p. eaay1809

[View in Scopus ↗](#) [Google Scholar ↗](#)

---

Cited by (142)

[Diabetes mellitus and Alzheimer's disease: Understanding disease mechanisms, their correlation, and promising dual activity of selected herbs](#)

2024, Journal of Ethnopharmacology

[Show abstract](#) 

## [Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects](#)

2024, Neurobiology of Disease

[Show abstract](#) 

## [Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins](#)

2024, Neuron

[Show abstract](#) 

## [Artificial intelligence for drug discovery and development in Alzheimer's disease](#)

2024, Current Opinion in Structural Biology

[Show abstract](#) 

## [The cell biology of APOE in the brain](#)

2024, Trends in Cell Biology

[Show abstract](#) 

## [ApoE maintains neuronal integrity via microRNA and H3K27me3-mediated repression](#)

2024, iScience

[Show abstract](#) 



[View all citing articles on Scopus](#) 

8  These authors contributed equally



ELSEVIER

All content on this site: Copyright © 2024 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.

RELX™